



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 235/34, 335/12, A61K 31/165, 31/17		A1	(11) International Publication Number: WO 00/50387
			(43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/KR00/00137			KIM, Hee-Doo [KR/KR]; College of Pharmacy, Sook-myung Women's University, 53-12, Chungpa-dong 2-ka, Yongsan-ku, Seoul 140-742 (KR).
(22) International Filing Date: 21 February 2000 (21.02.00)			(74) Agents: YOON, Dong-Yol et al.; 8th floor, Yeosam Building, 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).
(30) Priority Data: 1999/5751 22 February 1999 (22.02.99) KR			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): PACIFIC CORPORATION [KR/KR]; 181, Hankang-ro 2-ka, Yongsan-ku, Seoul 140-777 (KR).			
(71)(72) Applicant and Inventor: LEE, Jeewoo [KR/KR]; 27-901 Misung Apt., Apgujungdong, Kangnamku, Seoul 135-110 (KR).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): OH, Uhtaek [KR/KR]; College of Pharmacy, Seoul National University, San 56-1, Shilim-dong, Kwanak-ku, Seoul 151-742 (KR). PARK, Young-Ho [KR/KR]; No. 3-1201, Daelim Apartment, Sadang-dong, Dongjak-ku, Seoul 156-775 (KR). SUH, Young-Ger [KR/KR]; College of Pharmacy, Seoul National University, San 56-1, Shilim-dong, Kwanak-ku, Seoul 151-742 (KR). PARK, Hyeung-Geun [KR/KR]; College of Pharmacy, Seoul National University, San 56-1, Shilim-dong, Kwanak-ku, Seoul 151-742 (KR).			
(54) Title: VANILLOID ANALOGUES CONTAINING RESINIFERATOXIN PHARMACOPHORES AS POTENT VANILLOID RECEPTOR AGONISTS AND ANALGESICS, COMPOSITIONS AND USES THEREOF			
(57) Abstract			
The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for treating acute, chronic, inflammatory or neuropathic pains or for treating bladder hypersensitivity.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VANILLOID ANALOGUES CONTAINING RESINIFERATOXIN PHARMACOPHORES AS POTENT VANILLOID RECEPTOR AGONISTS AND ANALGESICS, COMPOSITIONS AND USES THEREOF

5

BACKGROUND OF THE INVENTION

1. Technical Field of the Invention

10

The present invention relates to vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and methods of using such analogues as vanilloid receptor agonists and potent analgesics.

15 2. Related Arts of the Invention

20 Capsaicin (CAP), which has the structure shown hereinafter, stimulates and then desensitizes sensory afferent C-fibers. The induced desensitization may have an application in arthritis, asthma, allergic responses including rhinitis, fever, pain, bladder hypersensitivity and the like.

25 Besides, the vanilloid receptor (VR) (or capsaicin receptor) is a specific neuronal membrane recognition site for CAP and related irritant compounds. It is expressed almost exclusively by primary sensory neurons involved in nociception and neurogenic inflammation. The receptor functions as a cation-selective ion channel with a preference for calcium, and its functional subtype, VR1, activated by both CAP and noxious heat has recently been cloned. Its desensitization caused by specific ligands has been 30 recognized as a promising therapeutic approach to mitigate neuropathic pain and other pathological conditions in which neuropeptides released from primary sensory neurons play a crucial role.

35 Most exogenous VR agonists which are being developed or used as analgesics are structurally related to CAP (i.e., ZostrixTM, OlvanilTM, SDZ-249482TM, and DA-5018TM) and resiniferatoxin. Their structures include a common vanilloid ring which appears to be important for agonist activity. However, in a recent report, it was demonstrated that compounds lacking the vanilloid moiety, such as sesquiterpenoid unsaturated

dialdehydes or triprenyl phenol, may also activate the receptor. Although receptor antagonists are fewer, several compounds such a capsazepine, which acts competitively at the CAP binding site, the channel blocker ruthenium red and capsazocaine have been reported.

5

Resiniferatoxin (RTX), a tricyclic diterpene isolated from *Euphorbia resinifera*, has been regarded as an ultrapotent CAP analogue. Indeed, the specific binding of RTX to the CAP binding site in dorsal root ganglia has been demonstrated with labeled [³H]RTX. RTX is being developed as an ultrapotent sensory neuron desensitizing agent for the treatment of urinary urge incontinence and the pain associated with diabetic neuropathy. Recently, a totally enantiocontrolled synthesis and a conformational analysis of RTX have been reported. However, the pharmacophoric groups of RTX have not yet been clearly defined, although structure-activity studies suggest that the C₂₀-homovanillic moiety, the C₃-keto group, and the ortho-ester phenyl group on ring C are crucial structural elements responsible for the extremely high potency of RTX. The lower potency of CAP relative to RTX, on the other hand, may be rationalized by the lack of some of these critical pharmacophoric groups, especially C₃-keto group.

10

15

20

25

30

35

USP 4,939,149 discloses a method for desensitizing a subject animal by administering a therapeutically effective desensitizing amount of RTX for desensitizing the animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to CAP.

Although a number of vanilloid agonist based on the structures of CAP and RTX have been reported as potential analgesics (e.g., USP 5,021,450 discloses homovanillyl diterpene derivatives such as 12-deoxyphorbol 13-phenylacetate 20-homovanillate and mezerein 20-homovanillate as mimics of RTX), these CAP-like analogues are limited by their intrinsic lower potency and narrow therapeutic index. RTX, on the other hand, is of limited availability from natural sources and is difficult to obtain synthetically due to its structural complexity.


The present inventors have made extensive researches to discover novel analgesic agents based on the vanilloid receptor, which has simpler structure than RTX or known RTX- or CAP-like analogues. As results thereof, we found that the new compounds having modifications on C₂₀-homovanillic moiety, the C₃-carbonyl, and the ortho-ester phenyl moiety as essential groups for recognition and binding showed potent vanilloid

agonist activity in terms of the receptor binding assay and the CAP-activated single channel assay.

5

SUMMARY OF THE INVENTION

Thus, the present invention provides novel compounds represented by the following formula (I) :



10

(I)

wherein,

X is an oxygen or sulfur atom;

15 A is -NHCH₂- or -CH₂-;

R₁ is a substituted or unsubstituted C₁₋₄alkylaryl group, or the group of formula : R₄CO- wherein R₄ is an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, or substituted or unsubstituted aryl group having 6 to 10 carbon atoms;

20 R₂ is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms or a halogen atom;

R₃ is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aminoalkyl, a diacid monoester or α -alkyl acid; and

25 the asteric mark * indicates a chiral carbon atom, and their pharmaceutically acceptable salts.

The present invention also provides pharmaceutical compositions comprising the

compound (I) as an active ingredient in an amount effective to alleviate pain, together with a pharmaceutically acceptable carrier.


5 The present invention also provides a use of the compounds as an active ingredient in medicines for treating pain or urinary incontinence.

The present invention still provides processes for preparing the compound (I).

10

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention is represented by the following formula (I) :



15

(I)

wherein,

X is an oxygen or sulfur atom;

A is $-\text{NH}-\text{CH}_2-$ or $-\text{CH}_2-$;

20 R_1 is a substituted or unsubstituted C_{1-4} alkylaryl group, or the group of formula : $\text{R}_4\text{CO}-$ wherein R_4 is an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, or substituted or unsubstituted aryl group having 6 to 10 carbon atoms;

25 R_2 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms or a halogen atom;


R_3 is an aminoalkyl, a diacid monoester or α -alkyl acid; and

the asteric mark * indicates a chiral carbon atom, and their pharmaceutically


acceptable salts.

The preferred compounds may be represented by the following formula (I-a) and (I-b):

5



(I-a)



(I-b)

10

wherein, R_1 , R_2 and R_3 have the same meanings as defined above.

In a preferred embodiment, the compounds have the general formula (I-a) or (I-b) wherein R_1 is the group of formula $\text{R}_4\text{CO}-$ wherein R_4 is an alkyl group having 1 to 18 carbon atoms; R_2 is an alkyl group having 1 to 6 carbon atoms; and R_3 is $-(\text{CH}_2)_n\text{NH}_2$, $-\text{CO}-(\text{CH}_2)_n\text{COOH}$ or $-(\text{CH}_2)_n\text{COOH}$, wherein n is an integer of 1 to 4. When R_1 or R_4 is a substituted aryl group, the substituents may be one or more lower alkyls having 1 to 4 carbon atoms or halogen atoms.

20 In a more preferred embodiment, the compounds have the general formula (I-a) or (I-b) wherein R_1 is the group of formula $\text{R}_4\text{CO}-$ wherein R_4 is an alkyl group having 1 to 6

carbon atoms; R₂ is an alkyl group having 1 to 6 carbon atoms; and R₃ is -CH₂CH₂NH₂, -COCH₂CH₂COOH or -CH₂COOH.

In all cases, the compound (I) may be in racemic mixture, or in R or S stereoisomer.
5 And, the present invention encompasses the compound (I) in the form of their pharmaceutically acceptable salts.

The compounds of the invention may be chemically synthesized by the methods in the reaction schemes hereinafter, which are merely exemplary and in no way limit the invention.
10 The reaction schemes show the steps for preparing the representative compounds of the present invention, and other compounds also may be produced by following the steps with appropriate modifications of reagents and starting materials, which are envisaged by those skilled in the art.

15 **GENERAL SYNTHETIC PROCEDURES**

The syntheses of 3-acyloxy-2-benzylpropyl thiourea derivatives (**7a-d**) are outlined in Schemes 1 and 2. Monoalkylation of diethyl malonate with various benzyl halides, followed by LiAlH₄-reduction, produced the corresponding diols (**2a-d**).
20 Monoacetylation of **2**, conversion of the remaining alcohol function to an azide, and deprotection of the acetyl group afforded the intermediate 3-azido-2-benzyl-1-propanols (**5a-d**). Acylation of **5a-d** with various acyl halides produced the corresponding esters **6a-d**, which following the reduction of the azide group were condensed with 4-methoxymethoxy-3-methoxybenzylisothiocyanate and hydrolyzed to the final desired products **7a-d**. The alternative ether analogues, represented by the 3-benzyloxy-2-benzylpropyl thiourea derivatives, **9a,c**, were synthesized from **5a,c** as shown in Scheme 2. Two chiral analogues of **7a-I** were synthesized from (R)-3-acetoxy-2-benzyl-1-propanol ((R)-**3a**) obtained from the enantioselective enzymatic acetylation of racemic 2-benzyl-1,3-propanediol (Scheme 3) following the same procedure for the synthesis of **7a-I**.
25

The synthesis of O-acetic acid analogues (**19a,b**) of above thiourea derivatives is represented in scheme 4. 4-Hydroxy-3-methoxy-benzonitrile (**11**) was protected by MOM (methoxymethylether) group to give **12**, whose cyano group was reduced to amine by LiAlH₄ and then protected by CBZ (chlorobenzyl) group to **13**. MOM group of **13** was deprotected and then the corresponding hydroxy group was alkylated by methyl bromoacetate to give **15**. Methyl ester of **15** was hydrolyzed and then CBZ group was
35


deprotected to give 17. Amine of 17 was condensed with isothiocyanate 18a,b to give final desired products 19a,b, respectively.



5 The synthesis of O-succinic ester analogues (23a,b) of above thiourea derivatives is represented in scheme 5. Mono benzyl ester of succinic acid 20 was acylated with vanilloid 14 to give 21 whose benzyl groups are deprotected by hydrogenation to give 22. Amine of 22 was condensed with isothiocyanate 18a,b to give final desired products 23a,b, respectively.

10 The synthesis of O-aminoethyl analogues (28a,b) of amide derivatives is represented in scheme 6. Azido group of 24 was reduced to amine, which in situ was condensed with homovanillic pentafluoro ester to give 25. Hydroxy group of 25 was alkylated by dibromoethane to give 26 whose bromo group then was substituted by azido group to 27. Reduction of 27a,b afforded the final desired products 28a,b, respectively.


15 The synthesis of O-aminoethyl analogues (36a,b) of above thiourea derivatives is represented in scheme 7. Amine of 4-hydroxy-3-methoxybenzylamine 29 was protected by Boc group and then hydroxy was alkylated by dibromoethane to give 31. Bromo group of 31 was substituted by azido group and then N-Boc was deprotected to give 33. Amine of 33 was converted into the correspond isothiocyanate which was condensed with azide 6 to give thiourea 35. Azido group of 35a,b was reduced to afford 20 final desired products 36a,b, respectively.

Scheme 1




Scheme 2**5 Scheme 3**

Scheme 4



(MOMCl : Chloromethylmethylether)

(CBZCl : Benzylchloroformate)

Scheme 5


5


(BnOH : Benzyl alcohol)

10

15

20


Scheme 6


Scheme 7

5

(Boc₂O : Di-*t*-butyl-di-carbonate)

TDP : 1,1-Thiocarbonyl di-2(1H)-pyridone)

10 Structure of Capsaicin (CAP)

Structure of RTX

5 The compounds of the present invention can be made into pharmaceutical compositions by combination with appropriate medical carriers or diluents. For example, the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents commonly used to prepare injectable solutions. Suitable carriers include, but not limited thereto, physiological saline, polyethylene glycol, ethanol, vegetable oils
 10 and isopropyl myristate. For topical application, the compounds of the invention can be formulated as an ointment or cream.

The pharmaceutical compositions comprising the compound of the present invention may be applied for the following occasions:

15

- to relieve pain caused by postherpetic neuralgia, diabetic neuropathy, postmastectomy pain syndrome, stump pain, reflex sympathetic dystrophy, trigeminal neuralgia, oral neuropathic pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paraesthetica, burning mouth syndrome
- 20
- to ameliorate pain such as intractable pain due to bilateral peripheral neuropathy
- to relieve itch due to psoriasis, hemodialysis, aquagenic pruritus, vulvar vestibulitis, 25 notalgia paraesthetica, brachioradial pruritus, Lichen simplex chronicus
- to treat cluster headache, vasomotor rhinitis or perennial allergic rhinitis in the form of intranasal drop

- to treat bladder hypersensitivity or spinal detrusor hyperreflexia in the form of intravesical solution.

5 The compound of the present invention has potent analgesic and antiinflammatory activity, and the pharmaceutical composition of the present invention thus may be employed to alleviate or relieve acute, chronic or inflammatory pains, suppress inflammation, or treat urge incontinence.

10 The following formulation methods and excipients are merely exemplary and in no way limit the invention.

15 The compounds of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.

20 The compounds of the present invention may be formulated into preparations for injections by dissolving, suspending, or emulsifying them in aqueous solvents such as normal saline, Dextrose 5%, or non-aqueous solvent such as vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol. The formulation may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

25 The desirable dose of the compounds of the present invention varies depending on the condition and weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer 0.0001 - 100 mg/kg, preferably 0.001 – 100 mg/kg by weight/day of the compounds of the present invention.

30 The dose may be administered in single or divided into several times per day. In terms of composition, the compounds should be present between 0.0001 to 10% by weight, preferably 0.0001 to 1% by weight based on the total weight of the composition.

35 The pharmaceutical composition of the present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can

be made orally, rectally or by intravenous, intramuscular, subcutaneous, intrathecal, epidural or intracerebroventricular injection.

5 EXAMPLES

General procedure for the synthesis of 1a-d

A cooled solution of diethylmalonate (6.4 g, 40 mmol) in DMF (20 mL) at 0 °C was treated with sodium hydride (60%, 1.92 g, 48 mmol) portionwise and stirred for 40 min 10 at room temperature. The reaction mixture was treated with the corresponding substituted benzyl chlorides (48 mmol) and stirred overnight at room temperature. The mixture was diluted with H₂O and extracted with EtOAc several times. The combined organic layer was washed with H₂O and brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with 15 EtOAc/hexane (1:10) as eluant to give 1.

Example 1 : Diethyl 3,4-dimethylbenzylmalonate (1b)

70% yield, colorless oil; ¹H NMR (CDCl₃) δ 6.9-7.05 (m, 3 H), 4.14 (m, 4 H, 2 x CO₂CH₂), 3.61 (t, 1 H, CH), 3.25 (d, 1 H, CH₂Ar), 3.14 (d, 1 H, CH₂Ar), 2.2-2.25 (m, 6 H, 2 x CH₃), 1.21 (m, 6 H, 2 x CO₂CH₂CH₃)

Example 2 : Diethyl 4-chlorobenzylmalonate (1c)

74% yield, colorless oil; ¹H NMR (CDCl₃) δ 7.25 (d, 2 H), 7.16 (d, 2 H), 4.14 (m, 4 H, 2 x CO₂CH₂), 3.60 (t, 1 H, CH), 3.18 (d, 2 H, CH₂Ar), 1.21 (t, 6 H, 2 x CO₂CH₂CH₃)

25

Example 3 : Diethyl 4-t-butylbenzylmalonate (1d)

74% yield, colorless oil; ¹H NMR (CDCl₃) δ 7.29 (d, 2 H), 7.13 (d, 2 H), 4.16 (q, 4 H, 2 x CO₂CH₂), 3.63 (t, 1 H, CH), 3.18 (d, 2 H, CH₂Ar), 1.30 (s, 9 H, C(CH₃)₃), 1.20 (t, 6 H, 2 x CO₂CH₂CH₃)

30

General procedure for the synthesis of 2a-d

A cooled solution of lithium aluminum hydride (3.64 g, 96 mmol) in diethyl ether (80 mL) at 0 °C was treated dropwise with a solution of 1 (24 mmol) in diethyl ether (20 mL). After stirring for 3 h at room temperature, the reaction mixture was cooled over an ice-bath and treated by successively by the dropwise addition of 3.5 mL of H₂O, 7 ml of 35 15% NaOH solution, and 10.5 mL of H₂O. The mixture was filtered by washing with

EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with EtOAc/hexane (3:1) as eluant to give 2.

Example 4 : 2-Benzyl-1,3-propanediol (2a)

5 98% yield, white solid, mp = 67 °C; ^1H NMR (CDCl_3) δ 7.15-7.30 (m, 5 H, phenyl), 3.74 (dd, 2 H, CH_2OH), 3.62 (dd, 2 H, CH_2OH), 2.9-3.0 (bs, 2 H, OH), 2.58 (d, 2 H, CH_2Ph), 2.03 (m, 1 H, CH).

Example 5 : 2-(3,4-Dimethylbenzyl)-1,3-propandiol (2b)

10 92% yield, colorless oil; ^1H NMR (CDCl_3) δ 6.88-7.06 (m, 3 H, phenyl), 3.6-3.8 (m, 4 H, 2 x CH_2OH), 2.5-2.7 (bs, 2 H, OH), 2.60 (d, 1 H, CH_2Ph), 2.52 (d, 1 H, CH_2Ph), 2.2-2.28 (m, 6 H, 2 x CH_3), 2.02 (m, 1 H, CH).

Example 6 : 2-(4-Chlorobenzyl)-1,3-propandiol (2c)

15 75% yield, white solid, mp = 64 °C; ^1H NMR (CDCl_3) δ 7.24 (d, 2 H), 7.10 (d, 2 H), 3.75 (dd, 2 H, CH_2OH), 3.61 (dd, 2 H, CH_2OH), 2.85 (bs, 2 H, OH), 2.58 (d, 2 H, CH_2Ph), 1.97 (m, 1 H, CH).

Example 7 : 2-(4-t-Butylbenzyl)-1,3-propandiol (2d)

20 80% yield, white solid, mp = 67 °C; ^1H NMR (CDCl_3) δ 7.31 (d, 2 H), 7.11 (d, 2 H), 3.81 (dd, 2 H, CH_2OH), 3.68 (dd, 2 H, CH_2OH), 2.58 (d, 2 H, CH_2Ph), 2.23 (bs, 2 H, OH), 2.05 (m, 1 H, CH), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

General procedure for the synthesis of 3a-d

25 A mixture of 2 (20 mmol), trimethylorthoacetate (3.6 g, 30 mmol) and a catalytic amount of p-toluenesulfonic acid in CH_2Cl_2 (40 mL) was stirred for 2 h at room temperature, and then treated with H_2O (0.54 g, 30 mmol). After stirring overnight at room temperature, the reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with EtOAc/hexane (1:2) as eluant to give 3.

Example 8 : 2-Benzyl-3-hydroxypropyl acetate (3a).

97% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.1-7.25 (m, 5 H, phenyl), 4.06 (ddd of AB, 2 H, CH_2OAc), 3.48 (m, 2 H, CH_2OH), 2.58 (ddd of AB, 2 H, CH_2Ph), 2.10 (m, 1 H, CH), 2.01 (s, 3 H, COCH_3)

Example 9 : (R)-2-Benzyl-1,3-propanediol ((R)-3a)

This compound was obtained from 2a by a published literature procedure (Tetrahedron Letters 30, 6189-6192 (1989)).

5 **Example 10 : 2-(3,4-Dimethylbenzyl)-3-hydroxypropyl acetate (3b)**

90% yield, colorless oil; ^1H NMR (CDCl_3) δ 6.88-7.06 (m, 5 H, phenyl), 4.13 (m, 2 H, CH_2OAc), 3.54 (m, 2 H, CH_2OH), 2.62 (m, 2 H, CH_2Ph), 2.2-2.3 (m, 6 H, 2 x CH_3), 2.10 (m, 1 H, CH), 2.07 (s, 3 H, COCH_3)

10 **Example 11 : 2-(4-Chlorobenzyl)-3-hydroxypropyl acetate (3c)**

86% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.25 (d, 2 H), 7.12 (d, 2 H), 4.12 (ddd of AB, 2 H, CH_2OAc), 3.53 (ddd of AB, 2 H, CH_2OH), 2.63 (ddd of AB, 2 H, CH_2Ph), 2.10 (m, 1 H, CH), 2.06 (s, 3 H, COCH_3).

15 **Example 12 : 2-(4-t-Butylbenzyl)-3-hydroxypropyl acetate (3d)**

84% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.30 (d, 2 H), 7.11 (d, 2 H), 4.13 (ddd of AB, 2 H, CH_2OAc), 3.56 (ddd of AB, 2 H, CH_2OH), 2.62 (ddd of AB, 2 H, CH_2Ph), 2.28 (s, 1 H, OH), 2.10 (m, 1 H, CH), 2.01 (s, 3 H, COCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

20 **General Procedure for the synthesis of 4a-d**

A cooled solution of 3 (12 mmol) and triethylamine (3.64 g, 36 mmol) in CH_2Cl_2 (20 mL) at 0 °C was treated dropwise with methanesulfonylchloride (2.06 g, 18 mmol). After stirring for 6 h at room temperature, the mixture was diluted with CH_2Cl_2 . The organic layer was washed with 1 N HCl, H_2O and brine, dried over MgSO_4 , and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc/hexane (1:3) as eluant to give the corresponding mesylate as an oil. The mesylate was dissolved in DMF (10 mL) and treated with sodium azide (2.2 g, 34 mmol). After 8 h of stirring at 80 °C, the reaction mixture was diluted with H_2O and extracted with EtOAc several times. The combined organic layer was washed with H_2O , dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc/hexane (1:15) as eluant to give 4.

Example 13 : 3-Azido-2-benzylpropyl acetate (4a)

92% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.15-7.35 (m, 5 H, phenyl), 4.05 (ddd of AB, 2 H, CH_2OAc), 3.34 (m, 2 H, CH_2N_3), 2.68 (d, 2 H, CH_2Ph), 2.22 (m, 1 H, CH), 2.08 (s, 3 H, COCH_3)

Example 14 : 3-Azido-2-(3,4-dimethylbenzyl)propyl acetate (4b)

85% yield, colorless oil; ^1H NMR (CDCl_3) δ 6.87-7.07 (m, 3 H), 4.04 (m, 2 H, CH_2OAc), 3.33 (m, 2 H, CH_2N_3), 2.69 (d, 1 H, CH_2Ph), 2.60 (d, 1 H, CH_2Ph), 2.1-2.3 (m, 7 H, 2 x CH_3 and CH), 2.07 (s, 3 H, COCH_3).

Example 15 : 3-Azido-2-(4-chlorobenzyl)propyl acetate (4c)

88% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.26 (d, 2 H), 7.12 (d, 2 H), 4.03 (ddd of AB, 2 H, CH_2OAc), 3.34 (m, 2 H, CH_2N_3), 2.65 (d, 2 H, CH_2Ph), 2.17 (m, 1 H, CH), 2.07 (s, 3 H, COCH_3).

Example 16 : 3-Azido-2-(4-t-butylbenzyl)propyl acetate (4d)

92% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.32 (d, 2 H), 7.08 (d, 2 H), 4.05 (ddd of AB, 2 H, CH_2OAc), 3.35 (ddd of AB, 2 H, CH_2N_3), 2.64 (d, 2 H, CH_2Ph), 2.20 (m, 1 H, CH), 2.07 (s, 3 H, COCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

General procedure for the synthesis of 5a-d

A solution of 4 (8 mmol) and a catalytic amount of K_2CO_3 in MeOH (10 mL) was treated with a couple of drops of H_2O . After stirring for 2 h at room temperature, the reaction mixture was quenched with several drops of acetic acid and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with $\text{EtOAc}/\text{hexane}$ (1:3) as eluant to give 5.

Example 17 : 3-Azido-2-benzyl-1-propanol (5a)

98% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.15-7.35 (m, 5 H, phenyl), 3.65 (m, 2 H, CH_2OH), 3.40 (ddd of AB, 2 H, CH_2N_3), 2.67 (ddd of AB, 2 H, CH_2Ph), 2.04 (m, 1 H, CH).

Example 18 : 3-Azido-2-(3,4-dimethylbenzyl)-1-propanol (5b)

92% yield, colorless oil; ^1H NMR (CDCl_3) δ 6.88-7.08 (m, 5 H, phenyl), 3.65 (m, 2 H, CH_2OH), 3.42 (m, 2 H, CH_2N_3), 2.68 (dd, 1 H, CH_2Ph), 2.60 (dd, 1 H, CH_2Ph), 2.2-2.3 (m, 6 H, 2 x CH_3), 2.03 (m, 1 H, CH).

Example 19 : 3-Azido-2-(4-chlorobenzyl)-1-propanol (5c)

88% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.25 (d, 2 H), 7.10 (d, 2 H), 3.58 (m, 2 H, CH_2OH), 3.36 (m, 2 H, CH_2N_3), 2.63 (dd, 2 H, CH_2Ph), 2.1 (bs, 1 H, OH), 1.98 (m, 1 H,

CH).

Example 20 : 3-Azido-2-(4-t-butylbenzyl)-1-propanol (5d)

98% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.32 (d, 2 H), 7.10 (d, 2 H), 3.63 (ddd of AB, 2 H, CH_2OH), 3.39 (ddd of AB, 2 H, CH_2N_3), 2.62 (m, 2 H, CH_2Ph), 2.02 (m, 1 H, CH), 1.78 (bs, 1 H, OH), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

General Procedure for the synthesis of 6a-d

10 A cooled solution of **5** (1 mmol), triethylamine (4 mmol) and a catalytic amount of 4-dimethylaminopyridine in CH_2Cl_2 (5 mL) at 0 °C was treated with the corresponding acyl chloride (2 mmol). After 2-12 h of stirring at room temperature, the mixture was diluted with CH_2Cl_2 . The organic layer was washed with 1 N HCl, H_2O and brine, dried over MgSO_4 , and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with EtOAc/hexane (1:10-20) as eluant to give **6**.

15

Example 21 : 3-Azido-2-benzylpropyl pivalate (6a-I)

92% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.15-7.35 (m, 5 H, phenyl), 4.04 (ddd of AB, 2 H, CH_2OCO), 3.34 (ddd of AB, 2 H, CH_2N_3), 2.68 (d, 2 H, CH_2Ph), 2.21 (m, 1 H, CH), 1.23 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

20

Example 22 : 3-Azido-2-benzylpropyl 2-methylpropanoate (6a-II)

93% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.15-7.35 (m, 5 H, phenyl), 4.05 (ddd of AB, 2 H, CH_2OCO), 3.34 (m, 2 H, CH_2N_3), 2.68 (d, 2 H, CH_2Ph), 2.58 (m, 1 H, CHMe_2), 2.21 (m, 1 H, CH), 1.18 (dd, 6 H, 2 x CH_3).

25

Example 23 : 3-Azido-2-benzylpropyl hexanoate (6a-III)

90% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.14-7.35 (m, 5 H, phenyl), 4.05 (ddd of AB, 2 H, CH_2OCO), 3.34 (m, 2 H, CH_2N_3), 2.68 (d, 2 H, CH_2Ph), 2.32 (t, 2 H, OOCCH_2), 2.20 (m, 1 H, CH), 1.64 (m, 2 H), 1.2-1.4 (m, 4 H), 0.88 (distorted t, 3 H).

30

Example 24 : 3-Azido-2-benzylpropyl stearate (6a-IV)

78% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.14-7.35 (m, 5 H, phenyl), 4.05 (ddd of AB, 2 H, CH_2OCO), 3.33 (m, 2 H, CH_2N_3), 2.68 (d, 2 H, CH_2Ph), 2.32 (t, 2 H, OOCCH_2), 2.20 (m, 1 H, CH), 1.2-1.7 (m, 30 H), 0.88 (distorted t, 3 H).

35

Example 25 : 3-Azido-2-benzylpropyl benzoate (6a-V)

90% yield, colorless oil; ^1H NMR (CDCl_3) δ 8.04 (m, 2 H), 7.15-7.60 (m, 8 H), 4.35 (dd, 1 H, J = 5.1 and 11.2 Hz, BzOCH_2), 4.26 (dd, 1 H, BzOCH_2), 3.43 (ddd of AB, 2 H, J = 5.61, 5.85 and 12.42 Hz, CH_2N_3), 2.78 (m, 2 H, CH_2Ph), 2.35 (m, 1 H, CH).

5 **Example 26 : 3-Azido-2-(3,4-dimethylbenzyl)propyl pivalate (6b-I)**

94% yield, colorless oil; ^1H NMR (CDCl_3) δ 6.86-7.07 (m, 3 H), 4.04 (m, 2 H, CH_2OCO), 3.36 (m, 2 H, CH_2N_3), 2.70 (d, 1 H, CH_2Ph), 2.61 (d, 1 H, CH_2Ph), 2.1-2.3 (m, 7 H, 2 x CH_3 and CH), 1.23 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

10 **Example 27 : 3-Azido-2-(3,4-dimethylbenzyl)propyl benzoate (6b-V)**

95% yield, colorless oil; ^1H NMR (CDCl_3) δ 8.02 (m, 2 H), 7.57 (m, 1 H), 7.46 (m, 2 H), 6.8-7.07 (m, 3 H), 4.32 (m, 2 H, CH_2OCO), 3.45 (m, 2 H, CH_2N_3), 2.80 (d, 1 H, CH_2Ph), 2.71 (d, 1 H, CH_2Ph), 2.2-2.4 (m, 7 H, 2 x CH_3 and CH).

15 **Example 28 : 3-Azido-2-(3,4-dimethylbenzyl)propyl 3,4-dimethylbenzoate (6b-VI)**

84% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.77 (m, 2 H), 7.21 (m, 1 H), 6.9-7.07 (m, 3 H), 4.30 (m, 2 H, CH_2OCO), 3.44 (m, 2 H, CH_2N_3), 2.79 (d, 1 H, CH_2Ph), 2.70 (d, 1 H, CH_2Ph), 2.2-2.4 (m, 13 H, 4 x CH_3 and CH).

20 **Example 29 : 3-Azido-2-(4-chlorobenzyl)propyl pivalate (6c-I)**

86% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.27 (d, 2 H), 7.09 (d, 2 H), 4.02 (ddd of AB, 2 H, CH_2OCO), 3.33 (m, 2 H, CH_2N_3), 2.66 (d, 2 H, CH_2Ph), 2.18 (m, 1 H, CH), 1.23 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

25 **Example 30 : 3-Azido-2-(4-chlorobenzyl)propyl benzoate (6c-V)**

92% yield, colorless oil; ^1H NMR (CDCl_3) δ 8.01 (m, 2 H), 7.58 (m, 1 H), 7.46 (m, 2 H), 7.28 (d, 2 H), 7.13 (d, 2 H), 4.29 (ddd of AB, 2 H, CH_2OCO), 3.43 (m, 2 H, CH_2N_3), 2.75 (d, 2 H, CH_2Ph), 2.33 (m, 1 H, CH).

30 **Example 31 : 3-Azido-2-(4-t-butylbenzyl)propyl pivalate (6d-I)**

99% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.31 (d, 2 H), 7.08 (d, 2 H), 4.04 (ddd of AB, 2 H, CH_2OCO), 3.35 (m, 2 H, CH_2N_3), 2.65 (d, 2 H, CH_2Ph), 2.20 (m, 1 H, CH), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.23 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

35 **Example 32 : 3-Azido-2-(4-t-butylbenzyl)propyl benzoate (6d-V)**

88% yield, colorless oil; ^1H NMR (CDCl_3) δ 8.04 (m, 2 H), 7.57 (m, 1 H), 7.45 (m, 2 H),

7.32 (d, 2 H), 7.12 (d, 2 H), 4.31 (ddd of AB, 2 H, CH_2OCO), 3.44 (m, 2 H, CH_2N_3), 2.75 (d, 2 H, CH_2Ph), 2.35 (m, 1 H, CH), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

General procedure for the synthesis of 7a-d

5 A solution of 6 (0.5 mmol) and Lindler's catalyst (50 mg) in EtOH (5 mL) was hydrogenated under a hydrogen balloon for 2 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was dissolved in CH_2Cl_2 (5 mL) and treated with 4-[(methoxymethyl)oxy]-3-methoxybenzyl isothiocyanate (0.5 mmol). After stirring overnight at room temperature, the reaction mixture was concentrated and 10 the residue was purified by flash column chromatography on silica gel with EtOAc/hexane (1:1) as eluant to give the corresponding thiourea. The thiourea was dissolved in CH_2Cl_2 (2 mL) and treated with trifluoroacetic acid (1 mL). After 1 hr of stirring at room temperature, the mixture was quenched with solid NaHCO_3 , filtered, and the filtrate was concentrated. The residue was diluted with EtOAc, washed with 15 NaHCO_3 , H_2O and brine, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc/hexane (1:1) as eluant to give 7.

Example 33 : 2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothiaryl propyl pivalate (7a-I)

20 40% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.1-7.32 (m, 5 H, phenyl), 6.75-6.9 (m, 3 H, Ar), 6.27 (bt, 1 H, NH), 6.05 (bs, 1 H, NH), 5.63 (s, 1 H, OH), 4.40 (bd, 2 H, $J = 4.38$ Hz, NHCH_2Ar), 4.17 (dd, 1 H, $J = 3.9$ and 11.46 Hz, CH_2OCO), 3.87 (s, 3 H, OCH_3), 3.7-3.85 (m, 2 H, 1 H of CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.24 (ddd, 1 H, $J = 5.37$, 8.07 and 13.89 Hz, $\text{CHCH}_2\text{NHC=S}$), 2.61 (ddd of AB, 2 H, CH_2Ph), 2.33 (m, 1 H, CH), 1.23 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (neat): 3362, 1715, 1278, 1157; MS m/e 445 (M^++1). Anal. ($\text{C}_{24}\text{H}_{32}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

Example 34 : (R)-2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothiaryl propyl pivalate ((R)-7a-I)

30 (R)-enantiomer of 7a-I; This compound was obtained from (R)-3a following the same general procedure for 7a-I; $[\alpha]_D = -714$ (c, 0.22, CHCl_3)

Example 35 : (S)-2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothiaryl propyl pivalate ((S)-7a-I)

35 (S)-enantiomer of 7a-I; This compound was obtained from (R)-3a following the same general procedure for 7a-I; $[\alpha]_D = +695$ (c, 0.08, CHCl_3)

Example 36 : 2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl 2-methyl propanoate (7a-II)

35% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.13-7.30 (m, 5 H, phenyl), 6.75-6.87 (m, 3 H, Ar), 6.34 (bt, 1 H, NH), 6.30 (bs, 1 H, NH), 5.75 (s, 1 H, OH), 4.40 (bs, 2 H, NHCH_2Ar), 4.17 (dd, 1 H, J = 3.9 and 10.95 Hz, CH_2OCO), 3.84 (s, 3 H, OCH_3), 3.65-3.85 (m, 2 H, CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.28 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.60 (m, 3 H, CH_2Ph and CHMe_2), 2.30 (m, 1 H, CHCH_2Ph), 1.18 (dd, 6 H, 2 x CH_3); IR (neat): 3361, 1715, 1273, 1157; MS m/e 430 (M^+). Anal. ($\text{C}_{23}\text{H}_{30}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

10

Example 37 : 2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl hexanoate (7a-III)

34% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.1-7.3 (m, 5 H, phenyl), 6.75-6.9 (m, 3 H, Ar), 6.23 (bt, 1 H, NH), 6.11 (bs, 1 H, NH), 5.66 (s, 1 H, OH), 4.40 (bs, 2 H, NHCH_2Ar), 4.15 (dd, 1 H, J = 3.9 and 11.43 Hz, CH_2OCO), 3.86 (s, 3 H, OCH_3), 3.65-3.85 (m, 2 H, CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.29 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.61 (m, 2 H, CH_2Ph), 2.30 (m, 3 H, CH_2COO and CH), 1.65 (m, 2 H), 1.2-1.4 (m, 4 H), 0.88 (distorted t, 3 H); IR (neat): 3360, 1715, 1274, 1122; MS m/e 458 (M^+). Anal. ($\text{C}_{25}\text{H}_{34}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

20

Example 38 : 2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl stearate (7a-IV)

30% yield, colorless oil; ^1H NMR (CDCl_3) δ 7.1-7.3 (m, 5 H, phenyl), 6.75-6.9 (m, 3 H, Ar), 6.28 (bt, 1 H, NH), 6.17 (bs, 1 H, NH), 5.69 (s, 1 H, OH), 4.39 (bs, 2 H, NHCH_2Ar), 4.14 (dd, 1 H, J = 3.9 and 11.67 Hz, CH_2OCO), 3.87 (s, 3 H, OCH_3), 3.65-3.85 (m, 2 H, CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.30 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.60 (m, 2 H, CH_2Ph), 2.30 (m, 3 H, CH_2COO and CH), 1.2-1.7 (m, 30 H), 0.88 (distorted t, 3 H); IR (neat): 3363, 1731, 1274, 1031; MS m/e 626 (M^+). Anal. ($\text{C}_{37}\text{H}_{58}\text{N}_2\text{O}_4\text{S}$)

25

Example 39 : 2-Benzyl-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl benzoate (7a-V)

50% yield, white solid, mp = 90 °C; ^1H NMR (CDCl_3) δ 7.98-8.02 (m, 2 H), 7.58 (m, 1 H), 7.4-7.5 (m, 2 H), 7.1-7.32 (m, 5 H, phenyl), 6.72-6.85 (m, 3 H, Ar), 6.42 (bt, 1 H, NH), 6.31 (bs, 1 H, NH), 5.73 (s, 1 H, OH), 4.34-4.42 (m, 3 H, NHCH_2Ar and CH_2OCO), 4.05 (dd, 1 H, CH_2OCO), 3.7-3.85 (m, 4 H, OCH_3 and $\text{CHCH}_2\text{NHC=S}$), 3.38 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.6-2.78 (m, 2 H, CH_2Ph), 2.46 (m, 1 H, CH); IR (neat): 3360, 1714, 1274, 1121; MS m/e 464 (M^+). Anal. ($\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

Example 40 : 2-(3,4-dimethylbenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl pivalate (7b-I)

40% yield, white solid, mp = 47 °C; ^1H NMR (CDCl_3) δ 6.93-7.05 (m, 3 H), 6.77-6.9 (m, 3 H, Ar), 6.22 (m, 1 H, NH), 5.98 (bs, 1 H, NH), 5.61 (s, 1 H, OH), 4.37 (bs, 2 H, NHCH_2Ar), 4.17 (ddd of AB, 1 H, CH_2OCO), 3.87 (s, 3 H, OCH_3), 3.7-3.85 (m, 2 H, CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.27 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.60 (m, 2 H, CH_2Ph), 2.2-2.32 (m, 7 H, 2 x CH_3 and CH), 1.22 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (neat): 3360, 1714, 1279, 1159; MS m/e 474 (M^++2). Anal. ($\text{C}_{26}\text{H}_{36}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

10

Example 41 : 2-(3,4-dimethylbenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl benzoate (7b-V)

45% yield, white solid, mp = 44 °C; ^1H NMR (CDCl_3) δ 8.02 (m, 2 H), 7.59 (m, 1 H), 7.46 (m, 2 H), 6.9-7.06 (m, 3 H), 6.72-6.85 (m, 3 H, Ar), 6.33 (m, 1 H, NH), 6.13 (bs, 1 H, NH), 5.65 (s, 1 H, OH), 4.35-4.44 (m, 3 H, NHCH_2Ar and CH_2OCO), 4.05 (m, 1 H, CH_2OCO), 3.7-3.85 (m, 4 H, OCH_3 and $\text{CHCH}_2\text{NHC=S}$), 3.40 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.6-2.78 (m, 2 H, CH_2Ph), 2.44 (m, 1 H, CH), 2.2-2.3 (m, 6 H, 2 x CH_3); IR (neat): 3360, 1713, 1274, 1121; MS m/e 492 (M^+). Anal. ($\text{C}_{28}\text{H}_{32}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

20

Example 42 : 2-(3,4-dimethylbenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl 3,4-dimethylbenzoate (7b-VI)

55% yield, white solid, mp = 58 °C; ^1H NMR (CDCl_3) δ 7.75 (m, 2 H), 7.20 (m, 1 H), 6.9-7.06 (m, 3 H), 6.74-6.85 (m, 3 H, Ar), 6.39 (m, 1 H, NH), 6.07 (bs, 1 H, NH), 5.63 (s, 1 H, OH), 4.35-4.43 (m, 3 H, NHCH_2Ar and CH_2OCO), 4.05 (m, 1 H, CH_2OCO), 3.7-3.85 (m, 4 H, OCH_3 and $\text{CHCH}_2\text{NHC=S}$), 3.37 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.6-2.74 (m, 2 H, CH_2Ph), 2.41 (m, 1 H, CH), 2.2-2.35 (m, 12 H, 4 x CH_3); IR (neat): 3373, 1711, 1266, 1124; MS m/e 520 (M^+). Anal. ($\text{C}_{30}\text{H}_{36}\text{N}_2\text{O}_4\text{S}$) C, H, N, S.

30

Example 43 : 2-(4-Chlorobenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl pivalate (7c-I)

40% yield, white solid, mp = 62 °C; ^1H NMR (CDCl_3) δ 7.25 (d, 2 H), 7.10 (d, 2 H), 6.77-6.90 (m, 3 H, Ar), 6.38 (t, 1 H, NH), 6.25 (bs, 1 H, NH), 5.72 (s, 1 H, OH), 4.42 (bs, 2 H, NHCH_2Ar), 4.16 (ddd of AB, 1 H, CH_2OCO), 3.86 (s, 3 H, OCH_3), 3.7-3.85 (m, 2 H, CH_2OCO and $\text{CHCH}_2\text{NHC=S}$), 3.19 (m, 1 H, $\text{CHCH}_2\text{NHC=S}$), 2.59 (ddd of AB, 2 H, CH_2Ph), 2.32 (m, 1 H, CH), 1.22 (s, 9 H, $\text{C}(\text{CH}_3)_3$); IR (neat): 3360, 1714,

1279, 1159; MS m/e 479 (M⁺). Anal. (C₂₄H₃₁ClN₂O₄S) C, H, N, S.

Example 44 : 2-(4-Chlorobenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl benzoate (7c-V)

5 55% yield, white solid, mp = 57 °C; ¹H NMR (CDCl₃) δ 8.00 (m, 2 H), 7.60 (m, 1 H), 7.47 (m, 2 H), 7.27 (d, 2 H), 7.15 (d, 2 H), 6.76-6.90 (m, 3 H, Ar), 6.36 (t, 1 H, NH), 6.15 (bs, 1 H, NH), 5.61 (s, 1 H, OH), 4.40 (m, 3 H, NHCH₂Ar and CH₂OCO), 4.00 (dd of AB, 1 H, CH₂OCO), 3.86 (s, 3 H, OCH₃), 3.85 (m, 1 H, CHCH₂NHC=S), 3.31 (m, 1 H, CHCH₂NHC=S), 2.67 (ddd of AB, 2 H, CH₂Ph), 2.46 (m, 1 H, CH); IR (neat): 10 3373, 1711, 1266, 1124; MS m/e 499 (M⁺). Anal. (C₂₆H₂₇ClN₂O₄S) C, H, N, S.

Example 45 : 2-(4-t-butylbenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl pivalate (7d-I)

15 40% yield, yellow solid, mp = 52 °C; ¹H NMR (CDCl₃) δ 7.30 (d, 2 H), 7.09 (d, 2 H), 6.75-6.90 (m, 3 H, Ar), 6.27 (t, 1 H, NH), 6.10 (bs, 1 H, NH), 5.66 (s, 1 H, OH), 4.40 (bs, 2 H, NHCH₂Ar), 4.15 (dd of AB, 1 H, CH₂OCO), 3.86 (s, 3 H, OCH₃), 3.7-3.85 (m, 2 H, CH₂OCO and CHCH₂NHC=S), 3.27 (m, 1 H, CHCH₂NHC=S), 2.58 (ddd of AB, 2 H, CH₂Ph), 2.30 (m, 1 H, CH), 1.29 (s, 9 H, C(CH₃)₃), 1.22 (s, 9 H, C(CH₃)₃); IR (neat): 3360, 1714, 1277, 1158; MS m/e 500 (M⁺). Anal. (C₂₈H₄₀N₂O₄S) C, H, N, S.

20 **Example 46 : 2-(4-t-butylbenzyl)-3-[(4-hydroxy-3-methoxybenzyl)amino]carbothioyl}propyl benzoate (7d-V)**

25 50% yield, white solid, mp = 54 °C; ¹H NMR (CDCl₃) δ 8.02 (m, 2 H), 7.60 (m, 1 H), 7.46 (m, 2 H), 7.32 (d, 2 H), 7.14 (d, 2 H), 6.75-6.90 (m, 3 H, Ar), 6.28 (t, 1 H, NH), 6.06 (bs, 1 H, NH), 5.61 (s, 1 H, OH), 4.40 (m, 3 H, NHCH₂Ar and CH₂OCO), 4.08 (dd of AB, 1 H, CH₂OCO), 3.86 (s, 3 H, OCH₃), 3.80 (m, 1 H, CHCH₂NHC=S), 3.40 (m, 1 H, CHCH₂NHC=S), 2.68 (m, 2 H, CH₂Ph), 2.46 (m, 1 H, CH), 1.29 (s, 9 H, C(CH₃)₃); IR (neat): 3360, 1714, 1272, 1124; MS m/e 520 (M⁺). Anal. (C₃₀H₃₆N₂O₄S) C, H, N, S.

30 **Example 47 : N-[2-Benzyl-3-(benzyloxy)propyl]-N'-(4-hydroxy-3-methoxybenzyl)thiourea (9a)**

35 60% yield, colorless oil; ¹H NMR (CDCl₃) δ 7.10-7.30 (m, 10 H, 2 x Ph), 6.81 (d, 1 H, Ar), 6.60 (bs, 1 H, Ar), 6.56 (d, 1 H, Ar), 6.54 (bs, 1 H, NH), 5.64 (s, 1 H, OH), 4.35 (m, 4 H, NHCH₂Ar and PhCH₂O), 3.82 (s, 3 H, OCH₃), 3.50 (m, 2 H, BnOCH₂), 3.37 (bt, 2 H, CHCH₂NHC=S), 2.64 (m, 2 H, CH₂Ph), 2.20 (m, 1 H, CH); IR (neat): 3288, 1274, 1123; MS m/e 450 (M⁺). Anal. (C₂₆H₃₀N₂O₃S) C, H, N, S.

Example 48 : N-[3-benzyloxy-2-(4-chlorobenzyl)propyl]-N'-(4-hydroxy-3-methoxybenzyl)thiourea (9c)

white solid, mp = 37.5 °C; ^1H NMR (CDCl_3) δ 7.0-7.3 (m, 9 H), 6.5-6.84 (m, 3 H, Ar), 6.54 (bs, 1 H, NH), 6.30 (bs, 1 H, NH), 5.68 (s, 1 H, OH), 4.32 (m, 4 H, NHCH_2Ar and PhCH_2O), 3.82 (s, 3 H, OCH_3), 3.48 (m, 2 H, BnOCH_2), 3.34 (m, 2 H, $\text{CHCH}_2\text{NHC=S}$), 2.58 (m, 2 H, CH_2Ph), 2.16 (m, 1 H, CH); IR (neat): 3340, 1273, 1153; MS m/e 484 (M^+). Anal. ($\text{C}_{26}\text{H}_{29}\text{ClN}_2\text{O}_3\text{S}$) C, H, N, S.

Example 49 : 3-Methoxy-4-methoxymethoxy-benzonitrile (12)

A solution of 4-hydroxy-3-methoxy-benzonitrile (11, 1.5 g, 10 mmol) and diisopropylethylamine (2.7 mL, 15 mmol) in CH_2Cl_2 (50 mL) was treated with chloromethylmethylether (0.92 mL, 12 mmol) and stirred for 3 h. After diluted with CH_2Cl_2 , the mixture was washed with H_2O , dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:2) as eluant to give 12 as white solid (1.54 g, 80%).

^1H NMR (CDCl_3) δ 7.27 (s, 1H, Ar), 7.24 (s, 1H, Ar), 7.11(s, 1H, Ar), 5.29 (s, 2H, ArOCH_2), 3.99 (s, 3H, ArOCH_3), 3.51 (s, 3H, CH_2OCH_3)

Example 50 : (3-Methoxy-4-methoxymethoxy benzyl)carbamic acid benzyl ester (13)

A solution of 12 (1.54 g, 8 mmol) in THF (20 mL) was added dropwise to a stirred suspension of lithiumaluminum hydride (1.2 g, 32 mmol) in THF (30 mL). After refluxed for 4 h, the reaction mixture was cooled to 0 °C and quenched with 5 N NaOH to destroy excess LiAlH_4 . Precipitated aluminum salts were removed by filtration and the THF was evaporated. The residue was partitioned with ether and H_2O . The ether layer was washed with brine, dried over K_2CO_3 , filtered and concentrated in vacuo to give amine. The amine was dissolved in CH_2Cl_2 (15 mL) and the solution was treated with NEt_3 (1.16 mL, 8.3 mmol) and benzylchloro formate (1.18 mL, 8.3 mmol). After stirring for 2 h at room temperature, the reaction mixture was diluted with CH_2Cl_2 . The organic layer was washed with H_2O and brine, dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:2) as eluant to give 13 as white solid (0.795 g, 30%).

^1H NMR (CDCl_3) δ 7.34 (m, 5H, phenyl), 7.08 (d, 1H, Ar), 6.81(m, 2H, Ar), 5.21 (s, 2H, ArOCH_2), 5.14 (s, 2H, OCH_2Ph), 4.32 (d, 2H, NH_2COO), 3.85 (s, 3H, ArOCH_3), 3.50 (s, 3H, $\text{ArOCH}_2\text{OCH}_3$)

Example 51 : (4-Hydroxy-3-methoxybenzyl)carbamic acid benzyl ester (14)

A solution of 13 (0.795 g, 2.4 mmol) in CH_2Cl_2 (5 mL) was treated with trifluoroacetic acid (2.5 mL) slowly and stirred for 5 min at room temperature. After cooling to 0 °C, the reaction mixture was neutralized with saturated NaHCO_3 solution, diluted with H_2O and extracted with CH_2Cl_2 several times. The combined organic layer was washed with H_2O and brine, dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (2:1) as eluant to give 14 as white solid (680 mg, 99%).

10 ^1H NMR (CDCl_3) δ 7.34 (m, 5H, phenyl), 6.83 (m, 3H, Ar), 5.14 (s, 2H, OCH_2Ph), 4.30 (d, 2H, NH_2COO), 3.86 (s, 3H, ArOCH_3)

Example 52 : [4-(Benzylcarbamoyl)-2-methoxy-phenoxy]-acetic acid methyl ester (15)

15 A solution of 14 (0.287 g, 1 mmol) in acetone (20 mL) was treated with K_2CO_3 (0.552 g, 4 mmol) and methyl bromoacetate (0.14 mL, 1.5 mmol) and refluxed for 3 h. After cooling, the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (3:2) as eluant to give 15 as white solid (0.323 g, 90%).

20 ^1H NMR (CDCl_3) δ 7.28-7.33 (m, 5H, phenyl), 6.78 (m, 3H, Ar), 5.11 (s, 2H, COCH_2Ph), 4.76 (s, 2H, CH_2Ph), 4.28 (d, 2H, CH_2NHCO), 3.81 (s, 3H, ArOCH_3), 3.76 (s, 3H, COOCH_3)

Example 53 : [4-(Benzylcarbamoyl)-2-methoxy-phenoxy]-acetic acid (16)

25 A solution of 5 (0.323 g, 0.9 mmol) in THF (1 mL) was treated with 15% NaOH solution (1 mL) and stirred for 30 min at room temperature. The reaction mixture was neutralized with acetic acid, diluted with H_2O and extracted with CH_2Cl_2 several times. The combined organic layer was washed with H_2O , dried over MgSO_4 and concentrated in vacuo to give 16 as white solid (0.276 g, 89%).

30 ^1H NMR (DMSO) δ 7.72 (s, 1H, COOH), 7.17-7.33 (m, 5 H, phenyl), 6.81 (s, 1H, Ar), 6.67 (s, 2H, Ar), 5.02 (s, 2H, COCH_2Ph), 4.16 (s, 2 H, CH_2Ph), 4.09 (d, 2H, CH_2NHCO), 3.70 (s, 3H, ArOCH_3)

35 Example 54 : (4-aminomethyl-2-methoxy-phenoxy)acetic acid (17)

A solution of 16 (0.276 g, 0.8 mmol) in MeOH (5 mL) was treated with 10% palladium

on carbon (30 mg) and hydrogenated under a balloon of hydrogen for 30 min. The reaction mixture was filtrated and the filtrate was concentrated to give 17 as white solid (0.093 g, 55%) which was used to next step without further purification.

5 **General Procedure for the Synthesis of 19**

A solution of 17 (0.5 mmol) in DMF (1 mL) was treated with NEt₃ (1.0 mmol), stirred for 30 min and treated with a solution of isothiocyanate 18 (0.5 mmol) in DMF. After stirring for 24 h at room temperature, the reaction mixture was diluted with H₂O and extracted with EtOAc several times. The combined organic layer was washed H₂O and 10 brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using CH₂Cl₂:MeOH:AcOH (100:10:0.5) as eluant to give 19.

15 **Example 55 : 2,2-Dimethyl-propionic acid 2-[3-(4-carboxymethoxy-3-methoxy-benzyl)-thioureidomethyl]-3-(3,4-dimethyl-phenyl)-propyl ester (19a)**
yield 27%, white solid

¹H NMR (CDCl₃) δ 7.15-7.26 (m, 4H, Ar), 6.76 (m, 3H, Ar), 6.54 (m, 1H, NH), 4.53 (s, 2H, CH₂COOH), 4.45 (bs, 2H, NHCH₂Ar), 4.15 (ddd of AB, 1H, CH₂OC=O), 3.82 (s, 20 3H, OCH₃), 3.6-3.85 (m, 2H, CH₂OC=O and CHCH₂NHC=S), 3.26 (m, 1H, CHCH₂NHC=S), 2.60 (m, 2H, CH₂Ph), 2.20-2.28 (m, 7H, 2 x CH₃ & CHCH₂Ph), 1.23 (s, 9H, CO(CH₃)₃)

25 **Example 56 : 2,2-Dimethyl-propionic acid 3-(4-t-butyl-phenyl)-2-[3-(4-carboxy methoxy-3-methoxy-benzyl)-thioureidomethyl]-propyl ester (19b)**
yield 52%, white solid

¹H NMR (CDCl₃) δ 7.09-7.28 (m, 4H, Ar), 6.85 (m, 3H, Ar), 6.54 (m, 1H, NH), 4.58 (s, 2H, CH₂COOH), 4.46 (bs, 2H, NHCH₂Ar), 4.12 (ddd of AB, 1H, CH₂OC=O), 3.78 (s, 3H, OCH₃), 3.7-3.85 (m, 2H, CH₂OC=O and CHCH₂NHC=S), 3.26 (m, 1H, CHCH₂NHC=S), 2.58 (m, 2H, CH₂Ph), 2.32 (m, 1H, CHCH₂Ph), 1.28 (s, 9H, 30 ArC(CH₃)₃), 1.22 (s, 9H, CO(CH₃)₃)

Example 57 : Succinic acid monobenzyl ester (20)

A solution of benzyl alcohol (0.52 mL, 5 mmol) in THF (20 mL) was treated with NaH (60%, 0.2 g, 5 mmol) and succinic anhydride (0.502 g, 5 mmol) and refluxed for 4 h. 35 After cooling to room temperature, the reaction mixture was diluted with H₂O and extracted with EtOAc several times. The combined organic layer was washed H₂O and

brine, dried over $MgSO_4$ and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:1) as eluant to give **20** as white solid (0.866 g, 57%).

5 1H NMR ($CDCl_3$) δ 7.38 (s, 5H, phenyl), 5.15 (s, 2H, $PhCH_2$), 2.71 (m, 4H, $COCH_2CH_2CO$)

Example 58 : Succinic acid benzyl ester 4-(benzyloxycarbonylamino-methyl)-2-methoxy-phenyl ester (21)

10 A solution of **10** (0.866 g, 2.85 mmol) in CH_2Cl_2 (10 mL) was treated with **14** (2.85 mmol), dicyclohexylcarbodiimide (4.2 mmol) and 4-dimethylaminopyridine (0.42 mmol) successively and stirred for 24 h at room temperature. The reaction mixture was diluted with diethyl ether, precipitated solid was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (2:1) as eluant to give **21** as white solid (1.15 g, 85%).

15 1H NMR ($CDCl_3$) δ 7.30-7.36 (m, 10H, 2 x phenyl), 6.86 (m, 3H, Ar), 5.14 (d, 4H, $PhCH_2$), 4.34 (d, 2H, CH_2NH), 3.75 (s, 3H, $ArOCH_3$), 2.93 (t, 2H, $COCH_2CH_2CO$), 2.79 (t, 2H, $COCH_2CH_2CO$)

Example 59 : Succinic acid mono-(4-amino methyl -2-methoxy-phenyl) ester (22)

20 This compound was prepared from **11** by following the procedure for the synthesis of **17**.

yield 99%, yellow solid.

1H NMR ($DMSO$) δ 8.24 (t, 1H, COOH), 6.75 (m, 3H, Ar), 4.17 (d, 2H, CH_2NH), 3.73 (s, 3H, $ArOCH_3$), 2.44 (t, 2H, $COCH_2CH_2CO$), 2.34 (t, 2H, $COCH_2CH_2CO$)

25

General Synthesis for the Synthesis of 23

These compounds were prepared from **18** and **22** by following the procedure for the synthesis of **19**.

30 **Example 60 : Succinic acid mono-(4-{3-[3-(3,4-dimethyl-phenyl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl]-thioureidomethyl}-2-methoxy-phenyl) ester (23a)**
yield 17%, white solid

35 1H NMR ($CDCl_3$) δ 6.9-7.2 (m, 4H, Ar), 6.8 (m, 3H, Ar), 6.34 (m, 1H, NH), 4.56 (d, 2H, $NHCH_2Ar$), 4.04 (m, 1H, $CH_2OC=O$), 3.84 (s, 3H, OCH_3), 3.6-3.85 (m, 2H, $CH_2OC=O$ and $CHCH_2NHC=S$), 3.27 (m, 1H, $CHCH_2NHC=S$), 2.65 (m, 2H, CH_2Ph), 2.50 (s, 4H, $COCH_2CH_2CO$) 2.18-2.29 (m, 7H, 2 x CH_3 and $CHCH_2Ph$), 1.24 (s, 9H, $CO(CH_3)_3$)

Example 61 : Succinic acid mono-(4-[3-[3-(4-t-butyl-phenyl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl]-thioureidomethyl]-2-methoxy-phenyl) ester (23b)
yield 9%, white solid

5 ¹H NMR (CDCl₃) δ 7.07-7.32 (m, 4H, Ar), 6.82 (m, 3H, Ar), 6.59 (m, 1H, NH), 4.87 (m, 3H, NHCH₂Ar and CH₂OC=O), 4.12 (ddd of AB, 1H, CH₂OC=O), 3.85 (s, 3H, OCH₃), 3.7-3.89 (m, 2H, CH₂OC=O and CHCH₂NHC=S), 3.41 (m, 1H, CHCH₂NHC=S), 2.58 (m, 2H, CH₂Ph), 2.39 (t, 4H, COCH₂CH₂CO) 2.32 (m, 1H, CHCH₂Ph), 1.28 (s, 9H, ArC(CH₃)₃), 1.21 (s, 9H, CO(CH₃)₃)

10

General Procedure for the Synthesis of 25

A mixture of **24** (1.15 mmol) and homovanillic pentafluorophenyl ester (0.4 g, 1.15 mmol) in EtOAc (5 mL) was treated with Lindlar's catalyst and hydrogenated under a balloon of hydrogen for 7 h. The reaction mixture was filtered and the filtrate was 15 concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:2) as eluant to give **25**.

Example 62 : 2,2-Dimethyl-propionic acid 3-(3,4-dimethyl-phenyl)-2-{[2-(4-hydroxy-3-methoxy-phenyl)-acetylamino]-methyl}-propyl ester (25a)

20 yield 37%, oil

¹H NMR (CDCl₃) δ 6.68-7.02 (m, 6H), 5.96 (bs, 1H, NH), 4.00 (m, 1H, CH₂OCO), 3.87 (s, 3H, OCH₃), 3.80 (m, 1H, CH₂OCO), 3.46 (s, 2H, COCH₂Ar), 3.32 (m, 1H, CH₂NH), 3.13 (m, 1H, CH₂NH), 2.50 (d, 2H, CH₂Ph), 2.20 (m, 7H, 2 x CH₃ and CH), 1.20 (s, 9H, CO(CH₃)₃)

25

Example 63 : 2,2-Dimethyl-propionic acid 3-(4-t-butyl-phenyl)-2-{[2-(4-hydroxy-3-methoxy-phenyl)-acetylamino]-methyl}-propyl ester (25b)

yield 70%, oil

30 ¹H NMR (CDCl₃) δ 7.28-7.31 (d, 2H), 7.03-7.05 (d, 2H), 6.89 (d, 1H, Ar), 6.80 (d, 1H, Ar), 6.72 (d, 1H, Ar), 5.8 (bs, 1H, NH), 4.02 (m, 1H, CH₂OCO), 3.89 (s, 3H, OCH₃), 3.83 (m, 1H, CH₂OCO), 3.49 (s, 2H, COCH₂Ar), 3.34 (m, 1H, CH₂NH), 3.12 (m, 1H, CH₂NH), 2.56 (d, 2H, CH₂Ph), 2.13 (m, 1H, CH), 1.31 (s, 9H, C(CH₃)₃), 1.22 (s, 9H, CO(CH₃)₃)

35 **General Procedure for the Synthesis of 26**

A mixture of **25** (0.33 mmol), 40% KOH (0.24 mL), 40% tetrabutylammonium

hydroxide (0.02 mL, 0.03 mmol) and 1,2-dibromoethane (0.96 mL) was heated at 50 °C for 12 h. The reaction mixture was diluted with CH_2Cl_2 , washed with H_2O and brine, dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:2) as eluant to give 26.

5

Example 64 : 2,2-Dimethyl-propionic acid 2-({2-[4-(2-bromoethoxy)-3-methoxy phenyl]acetyl amino}methyl)-3-(3,4-dimethylphenyl)propyl ester (26a)

yield: 68%

^1H NMR (CDCl_3) δ 6.74–7.03 (m, 6H), 5.75 (bs, 1H, NH), 4.32 (t, 2H, OCH_2),

10 4.01 (m, 1H, CH_2OCO), 3.86 (s, 3H, OCH_3), 3.82 (m, 1H, CH_2OCO), 3.64 (t, 2H, CH_2Br), 3.47 (s, 2H, COCH_2Ar), 3.31 (m, 1H, CH_2NH), 3.10 (m, 1H, CH_2NH), 2.50 (d, 2H, CH_2Ph), 2.20 (m, 7H, 2 x CH_3 , and CH), 1.21 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

Example 65 : 2,2-Dimethyl-propionic acid 2-({2-[4-(2-bromoethoxy)-3-methoxy phenyl]acetyl amino}methyl)-3-(4-t-butylphenyl)propyl ester (26b)

yield 92%

^1H NMR (CDCl_3) δ 7.26–7.30 (d, 2H), 7.01–7.04 (d, 2H), 6.74–6.89 (m, 3H, Ar), 5.8

(bs, 1H, NH), 4.3 (t, 2H, OCH_2), 4.01 (m, 1H, CH_2OCO), 3.86 (s, 3H, OCH_3), 3.82 (m, 1H, CH_2OCO), 3.64 (t, 2H, CH_2Br), 3.47 (s, 2H, COCH_2Ar), 3.31 (m, 1H, CH_2NH), 3.10 (m, 1H, CH_2NH), 2.5 (d, 2H, CH_2Ph), 2.12 (m, 1H, CH), 1.30 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.22 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

General Procedure for the Synthesis of 27

A solution of 26 (0.22 mmol) in DMF (2 mL) was treated with sodium azide (0.044 g,

25 0.67 mmol) and heated at 100 °C for 8 h. The reaction mixture was diluted with H_2O and extracted with EtOAc. The combined organic layer was washed with H_2O and brine, dried over MgSO_4 and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:1) as eluant to give 27.

Example 66 : 2,2-Dimethyl-propionic acid 2-({2-[4-(2-azidoethoxy)-3-methoxy phenyl]acetyl amino}methyl)-3-(3,4-dimethylphenyl)propyl ester (27a)

yield 98%

^1H NMR (CDCl_3) δ 6.74–7.03 (m, 6H), 5.74 (bs, 1H, NH), 4.19 (t, 2H, OCH_2), 4.01

35 (m, 1H, CH_2OCO), 3.85 (s, 3H, OCH_3), 3.82 (m, 1H, CH_2OCO), 3.62 (t, 2H, CH_2N_3), 3.48 (s, 2H, COCH_2Ar), 3.29 (m, 1H, CH_2NH), 3.10 (m, 1H, CH_2NH), 2.50 (d, 2H, CH_2Ph), 2.04–2.26 (m, 7H, 2 x CH_3 and CH), 1.21 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

Example 67 : 2,2-Dimethyl propionic acid 2-(2-[4-(2-azidoethoxy)-3-methoxy phenyl]acetyl amino)methyl)-3-(4-t-butylphenyl)propyl ester (27b)
yield 81%

5 ^1H NMR (CDCl_3) δ 7.26–7.30 (d, 2H), 7.01–7.04 (d, 2H), 6.75–6.91 (m, 3H, Ar), 5.76 (bs, 1H, NH), 4.17 (t, 2H, OCH_2), 4.00 (m, 1H, CH_2OCO), 3.85 (s, 3H, OCH_3), 3.82 (m, 1H, CH_2OCO), 3.63 (t, 2H, CH_2N_3), 3.48 (s, 2H, COCH_2Ar), 3.31 (m, 1H, CH_2NH), 3.06 (m, 1H, CH_2NH), 2.54 (d, 2H, CH_2Ph), 2.12 (m, 1H, CH), 1.29 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.20 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

10

General Procedure for the Synthesis of 28

A solution of 27 (0.05 mmol) in MeOH (5 mL) was treated with 10% palladium on carbon (0.02 g) and hydrogenated under a balloon of hydrogen for 3 h. The reaction mixture was filtrated and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using CHCl_3 :MeOH: NH_4OH (9:1:0.1) as eluant to give 28.

15 **Example 68 : 2,2-Dimethyl propionic acid 2-(2-[4-(2-aminoethoxy)-3-methoxy phenyl]acetyl amino)methyl)-3-(3,4-dimethylphenyl)propyl ester (28a)**

20 yield 83%, white solid

25 ^1H NMR (CDCl_3) δ 6.73–7.23 (m, 6H), 5.73 (bs, 1H, NH), 4.13 (m, 3H, OCH_2 and CH_2OCO), 3.85 (s, 3H, OCH_3), 3.82 (m, 1H, CH_2OCO), 3.5 (m, 2H, COCH_2Ar), 3.23 (m, 2H, CH_2NH and CH_2NH_2), 3.09 (m, 2H, CH_2NH and CH_2NH_2), 2.50 (d, 2H, CH_2Ph), 2.04–2.26 (m, 7H, 2 x CH_3 and CH), 1.20 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

25

Example 69 : 2,2-Dimethyl propionic acid 2-(2-[4-(2-aminoethoxy)-3-methoxy phenyl]acetyl amino)methyl)-3-(4-t-butylphenyl)propyl ester (28b)

yield 99%, white solid

30 ^1H NMR (CDCl_3) δ 7.26–7.29 (m, 2H), 7.01–7.04 (d, 2H), 6.76–6.89 (m, 3H, Ar), 5.84 (bs, 1H, NH), 4.05 (m, 1H, CH_2OCO), 3.85 (m, 3H, OCH_3), 3.72 (m, 3H, CH_2OCO and OCH_2), 3.47 (s, 2H, COCH_2Ar), 3.30 (m, 1H, CH_2NH), 3.10 (m, 1H, CH_2NH), 2.75 (bs, 2H, CH_2NH_2), 2.52 (d, 2H, CH_2Ph), 2.12 (m, 1H, CH), 1.29 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.20 (s, 9H, $\text{CO}(\text{CH}_3)_3$)

35 **Example 70 : (4-Hydroxy-3-methoxybenzyl)carbamic acid *t*-butyl ester (30)**

A mixture of 4-hydroxy-3-methoxy benzylamine (29, 0.5 g, 2.64 mmol) and NET_3 ,

(0.054 g, 5.29 mmol) in H₂O (10 mL) was treated dropwise with a solution of di-*t*-butyl-di-carbonate (1.15 g, 5.29 mmol) in dioxane (1.5 mL) for 20 min. After stirring for 24 h at room temperature, the reaction mixture was extracted with CH₂Cl₂ several times. The combined organic layer was dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:1) as eluant to give **30** as oil (0.663 g, 99%).

5 ¹H NMR (CDCl₃) δ 6.74-7.00 (m, 3H, Ar), 5.65 (s, 1H, OH), 4.79 (bs, 1H, NH), 4.23 (d, 2H, NHCH₂), 3.87 (s, 3H, OCH₃), 1.43 (s, 9H, O(CH₃)₃)

10 **Example 71 : [4-(2-Bromo-ethoxy)-3-methoxy-benzyl]-carbamic acid *t*-butyl ester (31)**

This compound was prepared from **30** by following the same procedure for the synthesis of **26**. (EtOAc:Hex=1:3), yield 84%

15 ¹H NMR (CDCl₃) δ 6.78-6.89 (m, 3H, Ar), 4.81 (bs, 1H, NH), 4.29-4.33 (t, 2H, OCH₂), 4.24 (d, 2H, NHCH₂), 3.90 (s, 3H, OCH₃), 3.65 (t, 2H, CH₂Br), 1.46 (s, 9H, O(CH₃)₃)

Example 72 : (4-(2-Azido-ethoxy)-3-methoxy-benzyl]-carbamic acid *t*-butyl ester (32)

This compound was prepared from **21** by following the same procedure for the synthesis of **27**. (EtOAc:Hex=1:3), yield 98%, yellow solid

¹H NMR (CDCl₃) δ 6.78-6.87 (m, 3H, Ar), 4.83 (bs, 1H, NH), 4.24 (d, 2H, OCH₂), 4.15 (t, 2H, NHCH₂), 3.80 (s, 3H, OCH₃), 3.62 (t, 2H, CH₂N₃), 1.46 (s, 9H, (CH₃)₃)

Example 73 : (4-(2-Azidoethoxy)-3-methoxy-benzylamine trifluoroacetate (33)

25 A solution of **32** (0.103 g, 0.32 mmol) in CH₂Cl₂ (1 mL) was treated with trifluoroacetic acid and heated at 100 °C for 1 hr. The reaction mixture was concentrated in vacuo. The residue was diluted with toluene and concentrated in vacuo several times to give **33** as brown solid (0.115 g, 100%)

30 ¹H NMR (DMSO-d₆) δ 6.99-7.10 (m, 3H, Ar), 4.12 (t, 2H, OCH₂), 3.93 (s, 2H, ArCH₂), 3.76 (s, 3H, OCH₃), 3.62 (m, 2H, CH₂N₃)

Example 74 : 1-(2-Azidoethoxy)-4-isothiocyanatomethyl-2-methoxy benzene (34)

A solution of **33** (0.115 g, 0.33 mmol) in DMF (1.5 mL) was treated with NEt₃ (0.037 g, 0.36 mmol) and stirred for 1 h. The mixture was treated with 1,1-thiocarbonyl di-2(1H)-pyridone (0.084 g, 0.33 mmol) and stirred for 2.5 h at room temperature. The mixture was diluted with H₂O and extracted with diethyl ether several times. The combined

organic layer was washed with H_2O and brine, dried over $MgSO_4$ and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:2) as eluant to give 34 as oil (0.065 g, 74%)

5 1H NMR ($CDCl_3$) δ 6.75-6.91 (m, 3H, Ar), 4.65 (s, 2H, $CH_2N=C=S$), 4.20 (t, 2H, OCH_2), .3.90 (s, 3H, OCH_3), 3.62 (t, 2H, CH_2N_3)

General Procedure for the Synthesis of 35

A solution of 6 (0.27 mmol) in EtOH (5 mL) was treated with Lindler's catalyst (0.042 mg) and hydrogenated under a balloon of hydrogen for 2 h. The reaction mixture was 10 filtered and the filtrate was concentrated. The residue was dissolved in CH_2Cl_2 (5 mL) and treated with 34 (0.27 mmol). After stirring for 15 h at room temperature, the reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel using EtOAc:Hex (1:10) as eluant to give 35.

15 **Example 75 : 2,2-Dimethyl propionic acid 2-{3-[4-(2-azidoethoxy)-3-methoxy benzyl]thioureido methyl}-3-(3,4-dimethylphenyl)propyl ester (35a)**
yield 39%

20 1H NMR ($CDCl_3$) δ 6.81-7.04 (m, 6H), 6.25 (m, 1H, NH), 6.02 (bs, 1H, NH), 4.41 (bs, 2H, $NHCH_2Ar$), 4.14-4.17 (m, 3H, CH_2OCO and OCH_2), 3.85 (s, 3H, OCH_3), 3.76-3.85 (m, 2H, CH_2OCO and $CHCH_2NHC=S$), 3.60-3.63 (t, 2H, CH_2N_3), 3.21-3.28 (m, 1H, $CHCH_2NC=S$), 2.47-2.66 (m, 2H, CH_2Ph), 2.20-2.26 (m, 7H, 2 x CH_3 and CH), 1.22 (s, 9H, $CO(CH_3)_3$)

25 **Example 76 : 2,2-Dimethyl propionic acid 2-{3-[4-(2-azidoethoxy)-3-methoxy benzyl]thioureido methyl}-3-(4-t-butylphenyl)propyl ester (35b)**
yield 60%

30 1H NMR ($CDCl_3$) δ 7.3 (d, 2H), 7.08 (d, 2H), 6.9 (m, 3H, Ar), 6.28 (m, 1H, NH), 6.10 (bs, 1H, NH), 4.43 (bs, 2H, $NHCH_2Ar$), 4.2 (m, 3H, CH_2OCO and OCH_2) 3.85 (s, 3H, OCH_3), 3.74-3.95 (m, 2H, CH_2OCO and $CHCH_2NHC=S$), 3.60-3.63 (t, 2H, CH_2N_3), 3.26 (m, 1H, $CHCH_2NHC=S$), 2.6 (m, 2H, CH_2Ph), 2.30 (m, 1H, CH), 1.29 (s, 9H, $CO(CH_3)_3$)

General Synthesis for the Synthesis of 36

A solution of 35 (0.068 g, 0.13 mmol) in THF (2 mL) was treated with 35 triphenylphosphine (0.067 g, 0.25 mmol) and H_2O (4.5 mg, 0.25 mmol) and stirred for 24 h at room temperature. The reaction mixture was concentrated in vacuo and the

residue was purified by flash column chromatography over silica gel using CHCl₃:MeOH:NH₄OH (9:1:0.1) as eluant to give 36.

Example 77 : 2,2-Dimethyl propionic acid 2-{3-[4-(2-aminoethoxy)-3-methoxy

5 **benzyl]thioureido methyl}-3-(3,4-dimethylphenyl)propyl ester (36a)**

yield 49%

¹H NMR (CDCl₃) δ 6.77–7.04 (m, 6H), 6.47 (bs, 2H, NH), 4.43 (bs, 2H, NHCH₂Ar), 4.18 (ddd of AB, 1H, CH₂OCO), 3.98 (t, 2H, OCH₂), 3.81 (s, 3H, OCH₃), 3.71-3.77 (m, 2H, CH₂OCO and CHCH₂NHC=S), 3.06 (t, 2H, CH₂NH₂), 2.48-2.68 (m, 2H, CH₂Ph), 10 2.20 (m, 7H, 2 x CH₃ and CH), 1.23 (s, 9H, CO(CH₃)₃)

Example 78 : 2,2-Dimethyl propionic acid 2-{3-[4-(2-aminoethoxy)-3-methoxy

benzyl]thioureido methyl}-3-(4-t-butylphenyl)propyl ester (36b)

yield 99%

15 ¹H NMR (CDCl₃) δ 7.28–7.47 (m, 2H), 7.2 (d, 2H), 6.8–7.0 (m, 3H, Ar), 6.4 (bs, 1H, NH), 4.44 (bs, 2H, NHCH₂Ar), 4.18 (m, 1H, CH₂OCO), 3.82 (t, 2H, OCH₂), 3.78 (s, 3H, OCH₃), 3.66-3.82 (m, 2H, CH₂OCO and CHCH₂NHC=S), 3.09 (t, 2H, CH₂NH₂), 2.48-2.68 (m, 2H, CH₂Ph), 2.20 (m, 1H, CH), 1.28 (s, 9H, C(CH₃)₃), 1.22(s, 9H, CO(CH₃)₃)

20 **Experimental Example 1 : Receptor binding affinity and CAP-activated channel assay**

The CAP-like activity of the target compounds was measured by an *in vitro* receptor binding assay and a CAP-activated single channel activation assay. In the receptor binding assay, the compounds were evaluated for their ability to displace bound [³H]RTX from the receptor. The results are expressed in terms of K_i values (mean ± SEM, 3 experiments) which represent the concentration of the non-radioactive ligand that displaces half of the bound labeled RTX. In the CAP-activated single channel activation assay, the increase of inward current resulting from the nonselective cation influx was measured following the extracellular application of the compounds to cultured neonatal rat dorsal root ganglion (DRG) neurons. The activities of the compounds are expressed in terms of the relative difference in ion conductance compared to CAP as a control.

Methods

1. [³H]Resiniferatoxin binding assay.

[³H]RTX (37Ci/mmol) was synthesized by the Chemical Synthesis and Analysis Laboratory, NCI-FCRDC. Nonradioactive RTX and capsazepine were purchased from LC Laboratories (Woburn, MA).

5 Inhibition of [³H]RTX binding in the presence of competing ligands was determined on membrane preparations from rat spinal cord. Membrane preparations were prepared as described (Methods in Neurosciences Vol 8, pp 368-380). Briefly, animals were euthanized under general anesthesia and the entire spinal cord was removed aseptically. Samples were disrupted with the aid of an Omni 2000 tissue homogenizer in ice-cold 10
10 mM HEPES, pH 7.4, containing 5 mM KCl, 5.8 mM NaCl, 2 mM MgCl₂, 0.75 mM CaCl₂, 12 mM D-glucose, and 137 mM sucrose ("Buffer A"). Homogenates were centrifuged at 1,000 x g for 10 min at 4 °C; pellets were resuspended in Buffer A and
15 recentrifuged at 35,000 x g for 40 min at 4 °C. The pellets from the second centrifugation were resuspended in the same buffer at an approximate protein concentration of 2 mg/ml, quick frozen on dry ice as small aliquots, and stored at -70 °C until assayed.

Experiments were designed to assess inhibition of specific [³H]RTX binding to membranes by non-radioactive compounds. [³H]RTX (100 pM) was incubated in the presence of competing ligand in a total volume of 300 :1 with 100 g membrane
20 protein for 60 min at 37 °C in Buffer A supplemented with 0.25 mg/ml bovine serum albumin (type V, Sigma) . The bovine serum albumin was included to reduce nonspecific adsorption of RTX to surfaces. At the end of the incubation, tubes were chilled on ice and 100µg of "α,-acid glycoprotein (Sigma) in a 50 : 1 volume was added to each tube to reduced nonspecific binding. Bound and free [³H]RTX were then
25 separated by pelleting the membranes by centrifugation at 10,000 x g for 15 min at 4 °C. The tips of the tubes containing the pellets were cut off, and the bound radioactivity was determined by scintillation counting. Nonspecific binding was determined in the presence of 1 mM non-radioactive RTX. Measurements of binding were determined in triplicate in each experiment, and each experiment was repeated at least two times. In
30 each experiment, competition curves were determined typically using 5 – 6 concentrations of competing ligand.

Binding was expressed as fmol/mg protein. Protein concentration was measured using the Bio-Rad protein assay according to the manufacturer's protocol (Bio-Rad Laboratories, CA). Samples were equilibrated in scintillation fluid for 10 hrs before
35 scintillation counting began and each sample was counted for 5 min. Binding data were

analyzed by fitting to the following equation :

$$B = ((L_H + L_C * K_d / K_i)^{(n-1)} / (K_d^n + (L_H + L_C * K_d / K_i)^n)) / (L_H^{n-1} / (K_d^n + L_H^n))$$

where L_C is the concentration of the non-radioactive ligand and K_i is the concentration of the free non-radioactive ligand at which it occupies half of the binding sites. B represents specifically bound [³H]RTX, B_{max} is the receptor density, L_H is the concentration of free [³H]RTX, K_d is the concentration of [³H]RTX at which half of the receptors are occupied and n is the cooperativity index referred to as the Hill coefficient.

2. Capsaicin-activated single channel assay.

10 *Cell Preparation* . Cultured DRG neurons were prepared as described previously(J. Neuroscience 16, 1659-1667, (1996)). Briefly, DRGs were dissected from all levels of lower cervical, thoracic and lumbar spinal cord of 1 or 2 day old neonatal rats. DRGs were collected in cold culture medium (4 °C) containing DMEM/F-12 mixture (Gibco, Grand Island, NY), fetal bovine serum (10%, Gibco), 1 mM sodium pyruvate, 25 ng/ml 15 nerve growth factor (Sigma, St. Louis, MO), and 100 units/ml of penicillin/streptomycin (Sigma). Ganglia were washed 3 times with DMEM/F-12 medium and incubated for 30 minutes in the DMEM/F-12 medium containing 1 mg/ml collagenase (Type II, Worthington Biomedical, Freehold, NJ). The ganglia were then washed 3 times with Mg²⁺- and Ca²⁺-free Hank's solution and incubated with gentle shaking in the warm (37 °C) 20 Hank's solution containing 2.5 mg/ml trypsin (Gibco). The solution was centrifuged at 1,000 rpm for 10 min, and the pellet was washed 2 or 3 times with the culture medium to inhibit the enzyme. The pellet was suspended in the culture medium and gently triturated with a Pasteur pipette. The suspension was plated on round glass coverslips (Fisher, Pittsburgh, PA) placed in small Petri dishes. The glass coverslips were treated overnight 25 with poly-L-lysine (Sigma) and dried before use. Cells were incubated at 37 °C in 95% air/ 5% CO₂ gas mixture. Cells were used 2-4 days after plating.

30 *Current recording*. Borosilicate glass pipettes (Narishige Scientific Instrument Lab., Tokyo) were pulled and coated with Sylgard (Dow Corning Co., Midland, MI). Tip resistances were about 2 and 5 Mohms for whole-cell and single-channel current recordings, respectively. After gigaseals were formed with the glass pipettes, cell-attached and inside-out patch configurations were used to study single-channel currents as described by Hamill et al. A salt bridge (1% agar in 300 mM KCl) immersed in bath and an Ag/AgCl reference electrode in pipette solution was used to minimize changes in 35 junctional potentials. Junctional potentials were canceled before gigaseals were formed. For whole-cell recording, the cell membrane under a glass pipette was ruptured by a gentle

suction. After forming a whole-cell, capacitative transient was canceled. Single-channel currents were recorded using a patch-clamp amplifier (Axopatch 200A, Axon Instruments, Foster City, CA) and filtered at 5 KHz with an 8-pole, low-pass Bessel filter. Data were digitized at 37 KHz with a digital data recorder (VR-10B, Instrutech, Great Neck, NY) and stored on videotapes for later analysis. For chart recording, output of amplifier was filtered at 500 Hz (Frequency Device, Haverhill, MA) and fed into a thermal array chart recorder (TA-240, Gould Instrument System, Valley View, OH). The digitized data stored on videotapes were imported to a personal computer (IBM pentium-compatible) for computer analysis of single-channel currents.

10

Channel open probability (P_o), amplitude and mean open time of single-channel currents were obtained using the pCLAMP software (Version 6.02, Axon Instruments). P_o of single channels was obtained from the ratio of the areas under the curves representing open events divided by the sum of the areas under the curves representing open and closed events. The half-amplitude algorithm in FETCHAN (Axon Instruments) was used for the threshold amplitude for detecting open events. Channel activity (NP_o) was calculated as a product of the number of channel (N) in the patch and P_o . NP_o or P_o was collected only from patches that contained less than 5 functional CAP-activated channels.

15

20 *Solutions.* Solutions in bath and pipette for single-channel recordings contained (in mM) 140 Na^+ , 2 Mg^{2+} , 144 Cl^- , 5 EGTA, and 10 HEPES at pH 7.2. For whole cell, pipette solution contained (in mM) 140 K^+ , 2 Mg^{2+} , 144 Cl^- , 5 EGTA, 10 HEPES, and 4 ATP at pH 7.2. The control perfusion solution for whole-cell recording contained (in mM) 140 Na^+ , 5 K^+ , 2 Mg^+ , 1 Ca^+ , 151 Cl^- , and 10 HEPES. The synthesized compounds were dissolved and stored in 100% ethanol to make 10 mM stock solutions. All other reagents used in cell-culture or in electrophysiological experiments were purchased from Sigma. All values were expressed as means \pm S.E.

25


30

Results

35 The results are presented in Table 1 and can be summarized as follows: (1) all the compounds tested, except 7b-Ia, showed stronger agonist activity and receptor binding affinity than CAP; (2) the thiourea analogue 7a-I ($K_i = 65.6$ nM) exhibited more potent agonist activity than the CAP-related amide analogue ($K_i = 404$ nM) reported in our earlier study; (3) the ester group in R_1 , which was designed to mimic the C_3 -carbonyl of

RTX, appears to be important for potent agonist activity relative to the benzyl ether analogues in R₁ [compare 7a-V ($K_i = 31.2$ nM) and 7c-V ($K_i = 148.7$ nM) with 9a ($K_i = 148$ nM) and 9c ($K_i = 659$ nM)] suggesting an important role for the carbonyl moiety in hydrogen-bonding to the receptor; (4) the pivaloyl group at R₁ and the 4-t-butylbenzyl group at R₂ proved to be effective hydrophobic groups resulting in optimal agonist activity for compounds 7b-I and 7d-I ($K_i = 19$ nM and 10.8 nM, respectively) which are ca. 280 and 490 times more potent than CAP; and (5) binding of thiourea to the receptor appears to be quite stereospecific as the two optically active enantiomers of 7a-I showed substantial differences in receptor binding affinity relative to the racemate [compare 7a-I ($K_i = 65.6$ nM) with (R)-7a-I ($K_i = 18.43$ nM) and (S)-7a-I ($K_i = 74$ nM)].

Table 1. Binding Affinities and Channel Activations



15

	R ₁	R ₂	R ₃	Affinities (nM)	Activations ^a
CAP				5,310 (± 370)	
RTX				0.023	
Amide	(CH ₃) ₃ CCO	H	H	404 (± 37)	++
7a-I	(CH ₃) ₃ CCO	H	H	65.6 (± 30.5)	+++
(R)-7a-I	(CH ₃) ₃ CCO	H	H	18.43 (± 5.1)	+++
10	(CH ₃) ₃ CCO	H	CH ₂ OCH ₃	146.2 (± 48)	++
(S)-7a-I	(CH ₃) ₃ CCO	H	H	74 (± 16)	++
7a-II	(CH ₃) ₂ CHCO	H	H	132.9 (± 75)	+++
7a-III	CH ₃ (CH ₂) ₄ CO	H	H	632.3 (± 48)	++
7a-IV	CH ₃ (CH ₂) ₁₆ CO	H	H	1,873 (± 351)	+
7a-V	PhCO	H	H	31.2 (± 9)	++

9a	PhCH ₂	H	H	148 (± 11)	++
7b-I	(CH ₃) ₃ CCO	3,4-diMe	H	19 (± 4.3)	++
7b-Ia	(CH ₃) ₃ CCO	3,4-diMe	CH ₂ OCH ₃	876 (± 65)	W
7b-V	PhCO	3,4-diMe	H	409 (± 178)	++
7b-VI	(3,4-Me)PhCO	3,4-diMe	H	183.5 (± 69)	+++
7c-I	(CH ₃) ₃ CCO	4-Cl	H	54.4 (± 16)	++
7c-V	PhCO	4-Cl	H	148.7 (± 11)	++
9c	PhCH ₂	4-Cl	H	659 (± 286)	++
7d-I	(CH ₃) ₃ CCO	4-t-Bu	H	10.8 (± 4)	++
7d-V	PhCO	4-t-Bu	H	60.2 (± 10)	++

^a + = CAP, ++ = 10 CAP, +++ = 100 CAP

Experimental Example 2 : Analgesic and Antiinflammatory Activity

5

The analgesic activity of some of the most potent capsaicin agonists, selected from the receptor binding and single channel assays, was evaluated in the PBQ-induced writhing assay and the results are shown in Table 2. As expected, two of the most potent compounds based on the *in vitro* assay, 7d-I and 7b-I, exhibited excellent analgesic 10 activities with ED₅₀ of 0.5 and 1 μ g/kg, respectively. Such values make these compound 300 to 600 times more potent than CAP. Both compounds were likewise more potent than olvanil or DA-5018, which are either currently available in the market or undergoing clinical trial as topical analgesics.

15 In the TPA-induced ear edema assay, even the most potent agonists of the inventive compounds showed weak antiinflammatory activity compared to the strong anti-edema activity of CAP (Table 2). We had originally speculated that the thiourea analogues, with their higher intrinsic potency, might dramatically reduce the TPA-induced ear edema. In this respect, their activity resembles that of olvanil or DA-5018, both of 20 which display weak topical activity in the TPA ear edema assay. Poor bioavailability through transcutaneous penetration may explain in part the weak topical antiinflammatory properties observed with these compounds.

25 The *in vitro* and analgesic activities of the compounds of the invention were evaluated by calcium-influx assay and acetic acid-induced writhing test, respectively.

As shown in Table 3, they all exhibited receptor agonistic activities comparable to capsaicin. Among them, aminoethyl analogues relatively displayed potent analgesic activities. Especially compound 28a was proved the most potent one and more potent than DA-5018 which are undergoing clinical trial as analgesic in Korea.

5

Methods

1. Mouse PBQ-induced writhing antinociceptive assay.

Male ICR mice (weight 25 g) were maintained in a controlled lighting environment (12 h on/ 12 h off). Animals received an intraperitoneal injection of 0.3 mL of the chemical irritant phenyl-p-quinone (4.5 mg/kg dissolved in saline containing 5% ethanol), and 6 minutes later the number of abdominal constrictions was counted in the subsequent 6 minutes period. Animals (10 animals/ group) received the synthesized compounds in 0.2 mL vehicle of ethanol/ Tween-80/ saline (10/ 10/ 80) intraperitoneally 15 30 min before the injection of phenyl-p-quinone. A reduction in the number of writhes responding to phenyl-p-quinone relative to the number responding in the saline control group was considered to be indicative of an antinociceptive effect. The data are expressed as ED₅₀ value to designate a 50% reduction in the number of writhes.

20 **2. Acetic acid-induced writhing test**

ICR mice (weight 20g) were maintained in a controlled lighting environment (12 h on/12 h off) and fasted overnight prior to testing. Animals received an intraperitoneal injection of 0.2 ml of an acetic acid solution (1.2 %), and 6 min later the number of abdominal constrictions was counted for a 6-min period. Mice (10 animals/group) were pretreated with drug or vehicle (10 ml/kg, i.p.) 1 hr before the injection of acetic acid. Test compounds were dissolved in ethanol/Tween-80/saline (10/10/80). Antinociceptive activity was expressed as the reduction in the number of abdominal constrictions, i.e. the difference between control animals (vehicle-pretreated mice) and animals pretreated with test compounds

30

3. TPA-induced mouse ear edema assay.

Male ICR mice (25-30 g), 10 animals/ group, were treated topically on the right ear with 25 μ L acetone or synthesized compound in acetone. Approximately 17 hours later, an identical treatment was applied. One hour later, 25 μ L of 0.5 nmol TPA in acetone was applied to the same ear. Five(5) hours following the application of TPA, the animals were sacrificed and ear punches (6 mm diameter) were weighed to the nearest 0.1 mg

on an electrobalance. The increased weight of the ear punch is a measure of inflammation (ear edema). Anti-inflammatory effects were expressed as percent inhibition of swelling in the compound-treated versus the control group. The percent inhibition is defined by the following equation.

$$\% \text{ Inhibition} = (C - T) / C \times 100$$

wherein C and T refer to increases in ear weight in TPA-treated and TPA + drug-treated groups, respectively.

4. ^{45}Ca uptake experiments

10 1) Culture of DRG neurons

DRG neurons were prepared from neonatal Sprague-Dawley rats by the method as previously described (Wood et al., 1988) with modification. In brief, DRGs of all spinal levels were dissected aseptically and collected. Ganglia were incubated sequentially for 30 min at 37°C in 200 U/ml collagenase and 2.5 mg/ml trypsin. The digestion was halted by addition of an equal volume of DME/F12 medium supplemented with 10% horse serum. The ganglia were then triturated through a fire-polished Pasteur pipette, filtered through nylon membrane, and spun down. Dissociated cells were plated onto Terasaki plates previously coated with 10 μ g/ml poly-D-ornithine at a density of 1500-1700 neurons/well. The cells were then cultured for 3-4 days in DME/F12 medium containing 1.2 g/l sodium bicarbonate, 15 mM HEPES, 50 mg/l gentamycin and 10% horse serum, diluted 1:1 with identical medium conditioned by C6 glioma cells (2 days on a confluent monolayer), in a humidified atmosphere at 37 °C containing 5% CO₂. Medium was supplemented with 200 ng/ml nerve growth factor. Cytosine arabinoside (100 μ M) was added for the first 2 days to kill dividing nonneuronal cells.

2) Uptake Experiment

Terasaki plates containing DRG neurons grown for 3-4 days were equilibrated with 4 washes of HEPES (10 mM, pH 7.4)-buffered calcium and magnesium-free Hank's balanced salt solution. The solution in each well was removed from the individual wells. Medium (10 μ l) containing the test concentration of compound plus 10 μ Ci/ml $^{45}\text{Ca}^{2+}$ was added to each well. The neurons were incubated at room temperature for 10 min, then the Terasaki plates were washed six times in HEPES (10 mM, pH 7.4)-buffered calcium and magnesium-free Hank's balanced salt solution and dried in an oven. 0.3% sodium dodecyl sulfate (10 μ l) was then added to dissolve the cells and extract the $^{45}\text{Ca}^{2+}$. The contents of each well were transferred to scintillation vials and counted in 3 ml of Aquasol-2 scintillant. Agonistic activities of test


compounds were calculated as percent of the maximal response of capsaicin at a concentration of 3 μ M and results are given as EC₅₀ \pm SEM.

Results

5 Table 2. PBQ-induced Writhing test and Ear Edema Assay


	Writhing Test ED ₅₀ (μ g/kg)	Relative Potency	Ear Edema Assay ID ₅₀ (μ g/ear)	Relative Potency
Capsaicin	300	1	3	1
RTX	0.01	30,000	0.002	1,500
Olvanil	30	10	30	0.1
DA-5018*	3	100	200	0.015
Indomethacin	400	0.75		
Aspirin	3,500	0.086		
Morphine	1,000	0.3		
7a-1	2	150	25	0.12
(R)-7a-I	8	38		
(S)-7a-I	9	33		
7a-II	15	20		
7a-III	5	60		
7a-IV	20	15		
7a-V	20	15	20	0.15
7b-I	0.5	600	18	0.17
7b-V	7	43	50	0.06
7b-VI	2	150	50	0.06
7c-I	5	60	22	0.14
7c-V	12	25	17	0.18
7d-I	1	300	5	0.6
7d-V	1.5	200	30	0.1

* DA-5018




2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide

Table 3. Calcium Influx Assay and Acetic Acid-Induced Writhing Assay



5

(I-a)



(I-b)

	R ₁	R ₂	R ₃	⁴⁵ Ca Influx (EC ₅₀ =μM)	Writhing Test (ED ₅₀ =μG/KG)
I-a					
19a	COC(CH ₃) ₃	3,4-(CH ₃) ₂	CH ₂ CO ₂ H	7.77±0.80	431
19b	COC(CH ₃) ₃	4-C(CH ₃) ₃	CH ₂ CO ₂ H	12.3±1.58	365
23a	COC(CH ₃) ₃	3,4-(CH ₃) ₂	COCH ₂ CH ₂ CO ₂ H	7.04±1.3	53.1
23b	COC(CH ₃) ₃	4-C(CH ₃) ₃	COCH ₂ CH ₂ CO ₂ H	7.00±1.2	60
36a	COC(CH ₃) ₃	3,4-(CH ₃) ₂	CH ₂ CH ₂ NH ₂	0.083±0.012	14.0
36b	COC(CH ₃) ₃	4-C(CH ₃) ₃	CH ₂ CH ₂ NH ₂	0.377±0.067	48.2

I-b					
28a	COC(CH ₃) ₃	3,4-(CH ₃) ₂	CH ₂ CH ₂ NH ₂	1.57±0.23	0.960
28b	COC(CH ₃) ₃	4-C(CH ₃) ₃	CH ₂ CH ₂ NH ₂	0.878±0.17	8.12
Olvanil					17.4
DA-5018				0.234	2.27
Capsaicin				0.435	

Experimental Example 3 : Pungency and Tachyphylaxis

5 The focus of medicinal chemistry in developing vanilloid-derived therapeutics has been the improvement of the bioavailability and the reduction of the excitatory properties. In connection with these objectives, the rat eye-wiping test was employed as an *in vivo* pungency test to assess the pain-producing effects of the compounds. As shown in Table 4, pungency profiles of selected potent agonists, 7a-V, 7b-I and 7d-I,
10 didn't follow the trend of the intrinsic agonistic activity measured by two *in vitro* assays. In this assay, RTX, an ultrapotent capsaicin analogue, was only 3-fold more potent than CAP and the selected compounds from our series were much less potent in evoking acute pain. A possible explanation for the reduced excitatory properties of these synthetic compounds (7b-I and 7d-I) could to lie in their rate of excitation of the
15 sensory neuron.

20 To check for the development of tachyphylaxis or cross-tachyphylaxis, a group of rats treated with the selected synthetic compounds were challenged 6 h posttreatment with 0.001% CAP. CAP, RTX and the synthetic analogues displayed an attenuated eye-wiping response in the test challenge equivalent to 0.001% of CAP, a result that is indicative of cross-tachyphylaxis between these classes of compounds. However, it should be noted that for CAP analogues a prior eye-wiping response is a prerequisite for the development of after-desensitization. In other words, non-irritating doses of CAP analogues were without effect to protect the eye-wiping movement by test treatment
25 with 0.001% CAP.

Methods

Pungency and tachyphylaxis in the rat eye-wiping test

The pain-inducing potency of the compounds was determined in the eye-wiping assay as previously described, and expressed quantitatively as follows. Solutions in tenfold increasing concentrations in physiological saline, containing at most 5% ethanol, were dropped into the eye of rats weighing 150-180 g, and the number of protective movement (eye-wiping with the foreleg) was counted. Each concentration was applied to 6 rats and the dose-response curves were obtained from the mean values. From the dose-response curves the concentrations having a moderate pain-producing potency (MPP), i.e. inducing an equal response of 10 scratchings, were calculated for each compound. On the basis of these concentrations the relative pain-producing potency (RPP) was determined as compared to that of capsaicin, which was taken as 100.

To check for the development of tachyphylaxis or cross-tachyphylaxis, 6 hours following the application of the test compound, a 0.001% test challenge of capsaicin was applied to the same eye. The % reduction of response to a concentration of 0.001% capsaicin in treated rats with the test compounds, compared to the vehicle-treated rats, was estimated to be the index of desensitization.

Results

Table 4. Eye-Wiping Test

	MPP(%) ^a	RPP ^b	% Reduction
Capsaicin	0.0003	100	55 (0.1) 35 (0.01)
RTX	0.0001	300	85 (0.01) 20 (0.001)
Olvanil	WP ^c	-	0.1
DA-5018	0.003	10	90 (0.1) 35 (0.01)
7a-V	WP	-	0 (0.1)
7b-I	0.002	15	90 (0.1) 30 (0.01) 5 (0.001)
7d-I	0.003	10	0 (0.1)

20

a : MPP: moderate pain-producing potency

b : RPP: relative pain-producing potency


c : WP : weakly pungent (less pungent than 0.001% capsaicin at 0.01% concentration)

25 The invention being thus described, it will be obvious that the same may be varied in

many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

CLAIMS

1. A compound represented by the following formula (I) :



5

(I)

wherein,

X is an oxygen or sulfur atom;

A is -NHCH₂- or -CH₂-;

10 R₁ is a substituted or unsubstituted C₁₋₄alkylaryl group, or the group of formula : R₄CO- wherein R₄ is an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, or substituted or unsubstituted aryl group having 6 to 10 carbon atoms;

15 R₂ is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms or a halogen atom;

R₃ is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aminoalkyl, a diacid monoester, α -alkyl acid; and

20 the asteric mark * indicates a chiral carbon atom, and its pharmaceutically acceptable salts.

2. A compound of Claim 1, wherein

25 R₁ is benzyl group or the group of formula : R₄CO- wherein R₄ is an alkyl group having 1 to 18 carbon atoms, phenyl group, or phenyl group substituted with one or more C₁₋₄ alkyl groups ;

R₂ is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 4 carbon atoms or a halogen atom; and

R_3 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, -(CH_2)_nNH₂-, -CO(CH_2)_nCO₂H or -(CH_2)_nCO₂H (wherein, n is 1 or 2).

3. A compound of Claim 1, wherein X is oxygen atom and A is -CH₂-.

5

4. A compound of Claim 1, wherein X is sulfur atom and A is -NHCH₂-.

5. A compound of Claim 1, wherein R_3 is a hydrogen atom, methyoxyethyl group, -CH₂CH₂NH₂, -COCH₂CH₂CO₂H or -CH₂CO₂H.

10

6. A compound of Claim 1, wherein R_2 is selected from the group of consisting of a hydrogen atom, t-butyl, 3,4-(dimethyl) and chloro atom.

15

7. A compound of Claim 1, wherein R_4 is selected from the group of consisting of t-butyl, i-propyl, pentyl, heptadecyl, phenyl and 3,4-(dimethyl)phenyl group.

20

8. A compound of Claim 1, which is one selected from the group of consisting of 2,2-dimethyl propionic acid 2-((2-[4-(2-aminoethoxy)-3-methoxyphenyl]acetylamino)methyl)-3-(3,4-dimethylphenyl)propyl ester;

2,2-dimethyl propionic acid 2-((2-[4-(2-aminoethoxy)-3-methoxyphenyl]acetylamino)methyl)-3-(4-tert-butylphenyl)propyl ester;

25

2,2-dimethyl propionic acid 2-benzyl 3-[3-(4-hydroxy-3-methoxybenzyl)thioureido]propyl ester;

2-methyl propionic acid 2-benzyl 3-[3-(4-hydroxy-3-methoxybenzyl)thioureido]propyl ester;

30

2,2-dimethyl propionic acid 2-(3,4-dimethylbenzyl)-3-[3-(4-hydroxy-3-methoxybenzyl)thioureido]propyl ester; and

35

2,2-dimethyl propionic acid 2-(4-tert-butylbenzyl)-3-[3-(4-hydroxy-3-methoxybenzyl)thioureido]propyl ester.

9. A pharmaceutical composition comprising the compound (I) as an active ingredient together with a pharmaceutically acceptable carrier.

10. A pharmaceutical composition of Claim 9, which comprises the compound (I) as an active ingredient in an amount effective to alleviate or relieve acute, chronic, inflammatory or neuropathic pains, suppress inflammation, or treat urge incontinence together with a pharmaceutically acceptable carrier.

11. An use of the compound (I) for manufacture of medicines employed for alleviating or relieving acute, chronic, inflammatory or neuropathic pains, suppressing inflammation, or treating urge incontinence.

12. A method of alleviating or relieving acute, chronic, inflammatory or neuropathic pains which comprises administering to a subject suffering from such pains the compound (I) in an amount effective amount of alleviating or relieving the pains.

13. A method of treating bladder hypersensitivity which comprises administering to a subject requiring such treatment the compound (I) in an amount effective amount of alleviating or relieving the pains.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 00/00137

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 07 C 235/34; C 07 C 335/12; A 61 K 31/165; A 61 K 31/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 07 C 235/34; C 07 C 335/12; A 61 K 31/165; A 61 K 31/17

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

QUESTEL: G-DARC; STN: CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Chemical Abstracts, Vol.132, No.7,14 February 2000 (14.02.00), (Columbus, Ohio, USA), J.LEE et al.: "3-Acyloxy-2-phenalkylpropyl amides and esters of homovanillic acid as novel vanilloid receptor agonists" Abstract No 78346f & Biorg. Med. Chem. Lett. 1999, 9(20), 2909-2914.	1-3,9,10
A	US 5021450 A (P.M.BLUMBERG), 04 June 1991 (04.06.91) claims. -----	1,9-13

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents:
 - ..A" document defining the general state of the art which is not considered to be of particular relevance
 - ..E" earlier application or patent but published on or after the international filing date
 - ..L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - ..O" document referring to an oral disclosure, use, exhibition or other means
 - ..P" document published prior to the international filing date but later than the priority date claimed
 - ..T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - ..X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - ..Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 - ..&.. document member of the same patent family

Date of the actual completion of the international search

27 June 2000 (27.06.00)

Date of mailing of the international search report

19 July 2000 (19.07.00)

Name and mailing address of the ISA/AT
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Hofbauer

Telephone No. 1/53424/225

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 00/00137

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US	A	5021450	04-06-1991	AT E 141585	15-09-1996
				AU A1 55614/90	07-01-1991
				AU B2 644363	09-12-1993
				CA A2 2057917	01-12-1990
				DE C0 69028203	26-09-1996
				DE T2 69028203	06-03-1997
				DK T3 474672	28-10-1996
				EP A1 474672	18-03-1992
				EP A4 474672	17-06-1992
				EP B1 474672	21-08-1996
				ES T3 2093645	01-01-1997
				JP T2 4503360	18-06-1992
				JP A2 9165333	24-06-1997
				JP B2 2694479	24-12-1997
				JP B2 3028290	04-04-2000
				WO A1 9015055	13-12-1990